WO2019022234A1

WO2019022234A1 - Inflammatory bowel disease therapeutic agent or prophylactic agent

Info

Publication number: WO2019022234A1
Application number: PCT/JP2018/028276
Authority: WO
Inventors: 新之助林; マーシャルバレット; 慎也横坂; 和也大角; 拓実青木; 目黒　裕之; 戒能　美枝; こずえ高垣; 雄大高橋
Original assignee: 東レ株式会社
Priority date: 2017-07-27
Filing date: 2018-07-27
Publication date: 2019-01-31
Also published as: JPWO2019022234A1

Abstract

The purpose of the present invention is to provide an inflammatory bowel disease therapeutic agent or prophylactic agent that has an RORγ antagonist activity. In order to achieve this purpose, the present invention provides an inflammatory bowel disease therapeutic agent or prophylactic agent that contains, as an active ingredient, a cyclic amine derivative represented by the indicated compound or a pharmacologically acceptable salt thereof.

Description

Therapeutic agent or preventive agent for inflammatory bowel disease

The present invention relates to a therapeutic or prophylactic agent for inflammatory bowel disease.

Inflammatory bowel disease is a generic term for diseases that cause chronic inflammation or ulceration in the mucosa of the large and small intestines, and mainly includes ulcerative colitis and Crohn's disease. Ulcerative colitis is a disease that shows nonspecific chronic inflammation that is more diffuse than the rectum and continuously affects the large intestine mucosa, and Crohn's disease is inflammation, deep ulcers and perforations in various parts of the digestive tract. It is a disease that exhibits full-thickness symptoms. Although the cause is unknown for all, various causes such as infection, environmental factors, psychosomatic problems, genetic or immune abnormalities are assumed, and it is generally considered that this is a multifactorial disease caused by complex entanglement. (Non-patent document 1).

For the treatment of inflammatory bowel disease, in particular for the treatment of ulcerative colitis, drug therapy, blood cell component removal therapy or surgical therapy is performed. As for drug therapy for inflammatory bowel disease, oral administration of salazosulfapyridine or 5-aminosalicylic acid is the basis, and if these effects are inadequate or more severe, corticosteroids and immunosuppressants are used It has been reported (Non-Patent Document 2). On the other hand, the treatment of Crohn's disease centers on nutrition therapy, drug therapy or surgery. With regard to drug therapy for Crohn's disease, it has been reported that 5-aminosalicylic acid preparations are used as a basis, and corticosteroids, immunosuppressants (Non-patent document 3), anti-TNF-α antibodies, etc. are used according to the symptoms. (Non-patent document 4).

In addition, various mechanisms have been proposed for the onset and pathogenesis of inflammatory bowel disease, and in recent years, one of them is Th17 cells, which is one of a subset of helper T cells, and inflammatory cytokines produced by it. It is reported that certain IL-17 plays an important role in the onset and progress of inflammatory bowel disease (Non-patent Document 5).

In recent years, it has become clear that the nuclear receptor retinoid-related orphan receptor γ (hereinafter, ROR γ) is important as a transcription factor essential for differentiation and proliferation of Th17 cells and expression of IL-17. In addition, it has been shown that suppression of RORγ expression or function suppresses the differentiation and activation of Th17 cells and the production of IL-17 (Non-patent Document 6), and lymphocytes from RORγ knockout mice are It has been reported that the transferred RAG deficient mouse alleviates the symptoms of colitis (Non-patent Document 7). Furthermore, it has been suggested that in order for RORγ to function as a transcription factor, binding between RORγ and a coactivator is necessary (Non-patent Document 8).

On the other hand, as RORγ antagonists, N- (5- (N- (4- (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) phenyl) sulfamoyl) has hitherto been described. 4-Methylthiazol-2-yl) acetamide (Non-patent Document 9) and 6- (2-Chloro-4-methylphenyl) -3- (4-cyclopropyl-5- (3-neopentylcyclobutyl) iso Substituted azole derivatives such as oxazol-3-yl) -5-oxohexanoic acid (Patent Document 1), N- (5- (2-chlorobenzoyl) -4- (3-chlorophenyl) thiazol-2-yl Sulfonylbenzene derivatives such as 2- (4- (ethylsulfonyl) phenyl) acetamide have been reported (Patent Document 2).

Moreover, as a compound having a cyclic amine structure such as 1-substituted piperidine-2-carboxamide, (S) -1- (2- (3,3-difluoropyrrolidin-1-yl) as a cannabinoid type 2 receptor agonist Acetyl) -N- (1-ethyl-5-phenyl-1H-1,2,4-triazol-3-yl) piperidine-2-carboxamide and the like have been reported (Patent Document 3), and acyl coenzyme A: diacylglycerol acyl As the converting enzyme 1 inhibitor, (R) -N- (5-benzyl-4-phenylthiazol-2-yl) -1- (2-cyclopentylacetyl) piperidine-2-carboxamide and the like have been reported.

Furthermore, as a compound having a cyclic amine structure such as 1-substituted piperidine-2-carboxamide, (S) -1- (2- (3,3-difluoropyrrolidin-1-yl) as a cannabinoid type 2 receptor agonist The use of acetyl) -N- (1-ethyl-5-phenyl-1H-1,2,4-triazol-3-yl) piperidine-2-carboxamide for therapeutic use in inflammatory bowel disease has been reported ( Patent Document 3).

JP 2012-236822 International Publication No. 2012/027965 International Publication No. 2010/096371 International Publication No. 2010/007046

However, currently known therapeutic agents for inflammatory bowel disease are not sufficiently satisfactory in alleviation of symptoms and alleviation of side effects, and new therapeutic agents for inflammatory bowel disease which solved or ameliorated these problems. Or development of a preventive agent is desired.

Patent Document 1 and Patent Document 2 do not disclose compounds having a cyclic amine structure such as 1-substituted piperidine-2-carboxamide.

Furthermore, Patent Document 3 does not show any specific efficacy data of the disclosed compound for inflammatory bowel disease, and Patent Document 4 discloses or suggests the action of the disclosed compound for RORγ. Not.

Then, this invention aims at providing the therapeutic agent or preventive agent of inflammatory bowel disease which has ROR (gamma) antagonist activity.

As a result of intensive studies to solve the above problems, the present inventors have found that a novel cyclic amine derivative having RORγ antagonist activity or a pharmacologically acceptable salt thereof is for the treatment or prevention of inflammatory bowel disease. It has been found to be effective, and the present invention has been completed.

That is, the present invention provides an agent for treating or preventing inflammatory bowel disease, which comprises a cyclic amine derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

[Wherein, R ¹ represents an alkyloxy group having 1 to 3 carbon atoms (wherein 1 to 3 arbitrary hydrogen atoms in the alkyloxy group may be substituted with a halogen atom), and R ² represents R ^2. Is a halogen atom, R ³ is a hydrogen atom, a halogen atom or a hydroxyl group, R ⁴ is a hydrogen atom or a halogen atom, and X is —C (= O) — (CH ₂ ) _n —R ⁵ or -S _{(= O)} represents 2 -R ^6, n represents an integer of 0 ~ 5, ^{R 5} is a hydrogen ^{^{atom, -OR 7, -SR 7, -S}} (= O) 2 -R ⁷ , -C (= O) -OR ⁷ , -N (R ⁷ ) R ⁸ , an alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms are substituted by a halogen atom) Or a heteroaryl group (wherein any hydrogen atom is an alkyl group having 1 to 3 carbon atoms). Is represents may.) Also have, R ⁶ represents an alkyl group having 1 to 5 carbon atoms, R ⁷ is an alkyl group (the alkyl group of which a hydrogen atom or a C 1-3, 1-3 And R ⁸ is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, an acyl group having 2 to 4 carbon atoms, or 1 to 3 carbon atoms). Represents an alkylsulfonyl group of ]

In the cyclic amine derivative represented by the above general formula (I), R ¹ is an alkyloxy group having 1 to 3 carbon atoms (in the alkyloxy group, 1 to 3 arbitrary hydrogen atoms are a fluorine atom or a chlorine atom) And R ² is a fluorine atom or a chlorine atom, R ³ is a hydrogen atom, a fluorine atom, a chlorine atom or a hydroxyl group, and R ⁴ is a hydrogen atom or a fluorine atom. Or R ⁵ is a hydrogen atom, -OR ⁷ , -SR ⁷ , -S (= O) ₂ -R ⁷ , -C (= O) -OR ⁷ , -N (R ⁷ ) R ⁸ , An alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms may be substituted with a fluorine atom or a chlorine atom) or a heteroaryl group (the heteroaryl group is And any hydrogen atom may be substituted with a methyl group). R ⁶ is an alkyl group having 1 to 3 carbon atoms, and R ⁷ is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms are fluorine atoms) Or a chlorine atom which may be substituted) is preferable.

In this case, higher RORγ antagonist activity can be expected.

In the cyclic amine derivative represented by the above general formula (I), R ¹ is a methoxy group (in the methoxy group, one to three arbitrary hydrogen atoms may be substituted with a fluorine atom). R ² is a fluorine atom or a chlorine atom, R ³ is a hydrogen atom, a fluorine atom or a hydroxyl group, R ⁴ is a hydrogen atom or a fluorine atom, n is an integer of 0 to 4 And R ⁵ is a hydrogen atom, -OR ⁷ , -N (R ⁷ ) R ⁸ , an alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms are substituted with a fluorine atom) Or a 5-membered ring heteroaryl group (in the 5-membered ring heteroaryl group, any hydrogen atom may be substituted with a methyl group), and R ⁶ is a methyl group or R ⁷ is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms (In the alkyl group, 1 to 3 arbitrary hydrogen atoms may be substituted with a fluorine atom), and R ⁸ is a hydrogen atom, a methyl group, an acyl group having 2 to 4 carbon atoms, or carbon More preferably, it is an alkylsulfonyl group of the number 1 to 3.

In this case, higher RORγ antagonist activity can be expected, and further, an excellent therapeutic effect or preventive effect in inflammatory bowel disease can be expected.

In the cyclic amine derivative represented by the above general formula (I), R ¹ is a trifluoromethoxy group, R ² is a chlorine atom, R ³ is a hydrogen atom, and R ⁴ is A hydrogen atom, X is -C (= O)-(CH ₂ ) _n -R ⁵ , n is an integer of 0 to 3, R ⁵ is a methyl group, a trifluoromethyl group,- N (R ⁷ ) R ⁸ , imidazolyl group, triazolyl group or tetrazolyl group (in the imidazolyl group, triazolyl group or tetrazolyl group, any hydrogen atom may be substituted with a methyl group), and R ⁷ is R ⁸ is more preferably a hydrogen atom, a methyl group, an acetyl group, a propionyl group, a methylsulfonyl group or an ethylsulfonyl group.

In another aspect, the invention relates to a method of treating or preventing inflammatory bowel disease, the cyclic amine derivative represented by the above general formula (I) in a subject in need of treating or preventing inflammatory bowel disease Or providing a method comprising the step of administering a pharmacologically acceptable salt thereof. The above-mentioned preferred embodiments relating to the cyclic amine derivative represented by the general formula (I) also apply to this embodiment.

In yet another aspect, the present invention provides a cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof for use in a method of treating or preventing inflammatory bowel disease I will provide a. The above-mentioned preferred embodiments relating to the cyclic amine derivative represented by the general formula (I) also apply to this embodiment.

In yet another aspect, the present invention provides a cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof for producing a therapeutic or prophylactic agent for inflammatory bowel disease Provide the use of The above-mentioned preferred embodiments relating to the cyclic amine derivative represented by the general formula (I) also apply to this embodiment.

The therapeutic agent or preventive agent for inflammatory bowel disease of the present invention can effectively suppress the function of RORγ and significantly improve the symptoms of inflammatory bowel disease.

FIG. 16 shows the inhibitory effect of the compound of Example 29 on the increase in gross injury score in a TNBS-induced rat colitis model. FIG. 16 shows the inhibitory effect of the compound of Example 57 on the increase in gross injury score in a TNBS-induced rat colitis model.

The therapeutic agent or preventive agent for inflammatory bowel disease of the present invention is characterized by containing a cyclic amine derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

The following terms used herein are as defined below unless otherwise indicated.

The "C1-C3 alkyl group" means a methyl group, an ethyl group, a propyl group or an isopropyl group.

The “alkyl group having 1 to 5 carbon atoms” means a linear or branched saturated hydrocarbon group having 1 to 5 carbon atoms or 3 to 5 carbon atoms, and examples thereof include a methyl group, Ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group or tert-pentyl group can be mentioned.

The "C1-C3 alkyloxy group" means a methoxy group, an ethoxy group, a propyloxy group or an isopropyloxy group.

The “C4 to C4 acyl group” means an acetyl group, a propionyl group, a butanoyl group or a 2-methylpropanoyl group.

The “C1-C3 alkylsulfonyl group” means a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group or an isopropylsulfonyl group.

"Heteroaryl group" means a heterocyclic aromatic group containing 1 to 4 hetero atoms arbitrarily selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, such as thienyl group, pyrrolyl group And furyl, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl.

The “5-membered ring heteroaryl group” is a heterocyclic aromatic ring containing 5 to 4 ring atoms, containing 1 to 4 heteroatoms optionally selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Group group, and examples thereof include thienyl group, pyrrolyl group, furyl group, thiazolyl group, imidazolyl group, oxazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, triazolyl group, oxadiazolyl group or tetrazolyl group.

The "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.

“The alkyl group having 1 to 3 carbon atoms (in the alkyl group, any one to 3 hydrogen atoms may be substituted with a halogen atom)” means the above-mentioned alkyl group having 1 to 3 carbon atoms 1 to 3 optional hydrogen atoms each independently represent a group which may be substituted by the above-mentioned halogen atom, and examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group and a fluoromethyl group. And a difluoromethyl group, a trifluoromethyl group, a 2-fluoroethyl group, a trifluoroethyl group, a trichloromethyl group or a trichloroethyl group.

“The alkyl group having 1 to 3 carbon atoms (in the alkyl group, any one to 3 hydrogen atoms may be substituted with a fluorine atom or a chlorine atom)” means the above-mentioned 1 to 3 carbon atoms 1 to 3 optional hydrogen atoms of the alkyl group in the above alkyl groups each independently represent a group which may be substituted with a fluorine atom or a chlorine atom, and examples thereof include a methyl group, an ethyl group, a propyl group and an isopropyl group. And fluoromethyl group, difluoromethyl group, trifluoromethyl group, 2-fluoroethyl group, trifluoroethyl group, trichloromethyl group or trichloroethyl group.

“The alkyl group having 1 to 3 carbon atoms (in the alkyl group, any one to 3 hydrogen atoms may be substituted with a fluorine atom)” means the above-mentioned alkyl group having 1 to 3 carbon atoms 1 to 3 optional hydrogen atoms may be substituted with a fluorine atom, and examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a fluoromethyl group, a difluoromethyl group and a trifluoro group. A methyl group, a 2-fluoroethyl group or a trifluoroethyl group can be mentioned.

The “C1-C3 alkyloxy group (in the alkyloxy group, one to three arbitrary hydrogen atoms may be substituted with a halogen atom)” means the above-mentioned C1-C3 alkyl 1 to 3 optional hydrogen atoms of the alkyloxy group each independently represent a group which may be substituted by the above-mentioned halogen atom, and examples thereof include a methoxy group, an ethoxy group, a propyloxy group and an isopropyloxy group. And fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, trifluoroethoxy, trichloromethoxy or trichloroethoxy.

The "C1-C3 alkyloxy group (in the alkyloxy group, one to three arbitrary hydrogen atoms may be substituted with a fluorine atom or a chlorine atom)" means that the above-mentioned carbon number 1 1 to 3 optional hydrogen atoms of the alkyloxy group of to 3 each independently represent a group which may be substituted with a fluorine atom or a chlorine atom, and examples thereof include a methoxy group, an ethoxy group and a propyloxy group. And isopropyloxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, trifluoroethoxy, trichloromethoxy and trichloroethoxy.

The term "methoxy group (the methoxy group may have 1 to 3 optional hydrogen atoms optionally substituted with a fluorine atom)" means a methoxy group, a fluoromethoxy group, a difluoromethoxy group or a trifluoromethoxy group. Do.

The “heteroaryl group (in the heteroaryl group, any hydrogen atom may be substituted with an alkyl group of 1 to 3 carbon atoms)” means one or more (for example, 1 to 6) of the above-mentioned heteroaryl groups. 4) optional hydrogen atoms each independently represent the group which may be substituted by the above-mentioned alkyl group having 1 to 3 carbon atoms, and examples thereof include a thienyl group, a pyrrolyl group, a furyl group and a thiazolyl group. Imidazolyl group, oxazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, triazolyl group, oxadiazolyl group, tetrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazinyl group, methyl thienyl group, dimethyl thienyl group, ethyl thienyl group Group, methyl pyrrolyl group, dimethyl pyrrolyl group, ethyl pyrrolyl group, methyl furyl group, Tyrfuryl group, ethyl furyl group, methyl thiazolyl group, dimethyl thiazolyl group, ethyl thiazolyl group, methyl imidazolyl group, dimethyl imidazolyl group, ethyl imidazolyl group, methyl oxazolyl group, dimethyl oxazolyl group, ethyl oxazolyl group, methyl Pyrazolyl group, dimethyl pyrazolyl group, ethyl pyrazolyl group, methyl isothiazolyl group, dimethyl iso thiazolyl group, ethyl iso thiazolyl group, methyl isoxazolyl group, dimethyl isoxazolyl group, ethyl isoxazolyl group, Methyl triazolyl group, dimethyl triazolyl group, ethyl triazolyl group, methyl oxadiazolyl group, dimethyl oxadiazolyl group, ethyl oxadiazolyl group, methyl tetrazolyl group, ethyl tetrazolyl group, methyl pyridyl Group, dimethylpi Dyl, ethyl pyridyl, methyl pyridazinyl, dimethyl pyridazinyl, ethyl pyridazinyl, methyl pyrimidinyl, dimethyl pyrimidinyl, ethyl pyrimidinyl, methyl pyrazinyl, dimethyl pyrazinyl, ethyl pyrazinyl Groups, methyltriazinyl group, dimethyltriazinyl group or ethyltriazinyl group.

The “heteroaryl group (in the heteroaryl group, any hydrogen atom may be substituted with a methyl group)” means any one or more (for example, 1 to 4) of the above heteroaryl groups. The hydrogen atoms each independently represent a group which may be substituted with a methyl group. For example, thienyl group, pyrrolyl group, furyl group, thiazolyl group, imidazolyl group, oxazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group Group, triazolyl group, oxadiazolyl group, tetrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazinyl group, methylthienyl group, dimethylthienyl group, dimethylthienyl group, methylpyrrolyl group, dimethylpyrrolyl group, methylfuryl group, dimethylfuryl group, Methyl thiazolyl group, dimethyl thiazolyl group, methyl imidazolyl group Group, dimethylimidazolyl group, methyloxazolyl group, dimethyloxazolyl group, methylpyrazolyl group, dimethylpyrazolyl group, methylisothiazolyl group, dimethylisothiazolyl group, methylisoxazolyl group, dimethylisoxazolyl group Group, methyl triazolyl group, dimethyl triazolyl group, methyl oxadiazolyl group, dimethyl oxadiazolyl group, methyl tetrazolyl group, methyl pyridyl group, dimethyl pyridyl group, methyl pyridazinyl group, dimethyl pyridad Examples include dinyl, methyl pyrimidinyl, dimethyl pyrimidinyl, methyl pyrazinyl, dimethyl pyrazinyl, methyl triazinyl and dimethyl triazinyl.

The “5-membered ring heteroaryl group (in the 5-membered ring heteroaryl group, any hydrogen atom may be substituted with a methyl group)” means one or more of the above-mentioned 5-membered ring heteroaryl groups ( For example, 1 to 4 optional hydrogen atoms each independently represent a group which may be substituted with a methyl group, and examples thereof include a thienyl group, a pyrrolyl group, a furyl group, a thiazolyl group, an imidazolyl group and an oxazolyl group. Group, pyrazolyl group, isothiazolyl group, isoxazolyl group, triazolyl group, oxadiazolyl group, tetrazolyl group, methylthienyl group, dimethylthienyl group, methylpyrrolyl group, dimethylpyrrolyl group, methylfuryl group, dimethylfuryl group, methylthiazolyl group, dimethylthiazolyl group Group, methyl imidazolyl group, dimethyl imidazolyl group, methyl oxazolyl group, dimethyl ester Ruxazolyl group, methyl pyrazolyl group, dimethyl pyrazolyl group, methyl isothiazolyl group, dimethyl iso thiazolyl group, methyl isoxazolyl group, dimethyl isoxazolyl group, methyl triazolyl group, dimethyl triazolyl group, methyl Examples include oxadiazolyl group, dimethyl oxadiazolyl group or methyl tetrazolyl group.

In the above-mentioned cyclic amine derivative, in the general formula (I), R ¹ is an alkyloxy group having 1 to 3 carbon atoms (1 to 3 optional hydrogen atoms of the alkyloxy group are each independently a fluorine atom or It is preferable that it may be substituted by a chlorine atom), and a methoxy group (one to three optional hydrogen atoms of the methoxy group may be independently substituted by a fluorine atom). And the trifluoromethoxy group is more preferable.

R ² is preferably a fluorine atom or a chlorine atom, and more preferably a chlorine atom.

R ³ is preferably a hydrogen atom, a fluorine atom, a chlorine atom or a hydroxyl group, more preferably a hydrogen atom, a fluorine atom or a hydroxyl group, and still more preferably a hydrogen atom.

R ⁴ is preferably a hydrogen atom, a fluorine atom or a chlorine atom, more preferably a hydrogen atom or a fluorine atom, and still more preferably a hydrogen atom.

It is preferable that X be -C (= O)-(CH ₂ ) _n -R ⁵ .

N is preferably an integer of 0 to 4, and more preferably an integer of 0 to 3.

R ⁵ is a hydrogen atom, -OR ⁷ , -SR ⁷ , -S (= O) ₂ -R ⁷ , -C (= O) -OR ⁷ , -N (R ⁷ ) R ⁸ , having 1 to 3 carbon atoms (1 to 3 optional hydrogen atoms of the alkyl group may be each independently substituted with a fluorine atom or a chlorine atom) or a heteroaryl group (one or more of the heteroaryl group And each hydrogen atom may be independently substituted with a methyl group), preferably a hydrogen atom, -OR ⁷ , -N (R ⁷ ) R ⁸ or an alkyl group having 1 to 3 carbon atoms. (1 to 3 optional hydrogen atoms of the alkyl group may be each independently substituted with a fluorine atom) or a 5-membered ring heteroaryl group (one or more of the 5-membered ring heteroaryl group Arbitrary hydrogen atoms may be each independently substituted with a methyl group ) More preferably, methyl group, trifluoromethyl group, -N (R 7) ^R ^8, imidazolyl group, triazolyl group or tetrazolyl group (said imidazolyl group, one or more optional a triazolyl group or a tetrazolyl group The hydrogen atoms may be each independently substituted with a methyl group).

R ⁶ is preferably an alkyl group having 1 to 3 carbon atoms, and more preferably a methyl group or an ethyl group.

R ⁷ is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms (1 to 3 optional hydrogen atoms of the alkyl group may be each independently substituted with a fluorine atom or a chlorine atom) It is preferable that it is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms (1 to 3 optional hydrogen atoms of the alkyl group may be each independently substituted with a fluorine atom). Preferably, a hydrogen atom, a methyl group or an ethyl group is more preferable.

R ⁸ is more preferably a hydrogen atom, a methyl group, an acyl group having 2 to 4 carbon atoms or an alkylsulfonyl group having 1 to 3 carbon atoms, and a hydrogen atom, a methyl group, an acetyl group, a propionyl group, a methylsulfonyl group Or an ethylsulfonyl group is more preferred.

Specific examples of preferable compounds of the cyclic amine derivative represented by the above general formula (I) are shown in Tables 1-1 to 1-3, but the present invention is not limited thereto.

The compounds described in Tables 1-1 to 1-3 also include their pharmacologically acceptable salts.

The cyclic amine derivative represented by the above general formula (I) may have a conformational isomer, a rotational isomer, a tautomer, an optical isomer, a diastereomer, etc., but only a single isomer. It also includes racemic and diastereomeric mixtures.

The cyclic amine derivative represented by the above general formula (I) may be labeled with one or more isotopes, and the isotopes to be labeled include, for example, ² H, ³ H, ¹³ C, ¹⁴ C , ¹⁵ N, ¹⁵ O, ¹⁸ O and / or ¹²⁵ I.

Examples of the “pharmaceutically acceptable salt” of the cyclic amine derivative represented by the above general formula (I) include a salt with an inorganic base, a salt with an organic base, a salt with an inorganic acid, and an organic acid Salt of Examples of salts with inorganic bases include alkali metal salts such as sodium salts or potassium salts, alkaline earth metal salts such as calcium salts or magnesium salts, ammonium salts, aluminum salts or zinc salts, and salts with organic bases Examples of the salt include salts with organic amines such as triethylamine, ethanolamine, morpholine, piperidine or dicyclohexylamine, and salts with basic amino acids such as arginine or lysine. Examples of salts with inorganic acids include hydrochlorides, sulfates, nitrates, hydrobromides, hydroiodides or phosphates, and salts with organic acids include, for example, oxalic acid. Salt, malonate, citrate, fumarate, lactate, malate, succinate, tartrate, acetate, trifluoroacetate, maleate, gluconate, benzoate, ascorbic acid Salt, glutarate, mandelate, phthalate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, aspartate, glutamate or cinnamate An acid salt etc. are mentioned.

The cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof may be an anhydride or may form a solvate such as a hydrate. . Here, as a solvate, a pharmacologically acceptable solvate is preferable. The pharmacologically acceptable solvate may be either hydrate or non-hydrate, but hydrate is preferred. Examples of the solvent constituting the solvate include alcohol solvents such as methanol, ethanol or n-propanol, N, N-dimethylformamide (hereinafter, DMF), dimethyl sulfoxide (hereinafter, DMSO) or water.

The cyclic amine derivative represented by the above general formula (I) (hereinafter, cyclic amine derivative (I)) can be produced by an appropriate method based on the characteristics derived from the basic skeleton and the type of substituent. Starting materials and reagents used for producing these compounds can be generally purchased or can be produced by known methods.

The cyclic amine derivative (I) and the intermediates and starting materials used for its preparation can be isolated and purified by known means. Known means for isolation and purification include, for example, solvent extraction, recrystallization or chromatography.

When the cyclic amine derivative (I) contains an optical isomer or stereoisomer, each isomer can be obtained as a single compound by a known method. Known methods include, for example, crystallization, enzymatic resolution or chiral chromatography.

In each reaction of the production method described below, when the raw material compound has an amino group or a carboxyl group, a protective group may be introduced to these groups, and after the reaction, the protective group is optionally deprotected. Thus, the target compound can be obtained.

As a protecting group of an amino group, for example, an alkylcarbonyl group having 2 to 6 carbon atoms (eg, acetyl group), benzoyl group, an alkyloxycarbonyl group having 2 to 8 carbon atoms (eg, tert-butoxycarbonyl group or benzyloxy) And a carbonyl group), an aralkyl group having 7 to 10 carbon atoms (eg, benzyl group) or a phthaloyl group.

Examples of the protecting group for the carboxyl group include, for example, an alkyl group having 1 to 6 carbon atoms (eg, methyl group, ethyl group or tert-butyl group) or an aralkyl group having 7 to 10 carbon atoms (eg, benzyl group).

The deprotection of the protective group is carried out according to known methods (for example, Greene, TW, "Greene's Protective Groups in Organic Synthesis"; Wiley-Interscience) or a modification thereof although it varies depending on the kind of protective group. be able to.

The cyclic amine derivative (I) is, for example, as shown in Scheme 1, a coupling reaction (step 1) of a boronic acid derivative (II) with an aryl halide derivative (III) in the presence of a metal catalyst and a base The condensation reaction of biphenylamine derivative (IV) obtained in the first step with the pipecolic acid derivative (V) in the presence of a condensing agent and a base (step 2), followed by the second step in the presence of an acid Deprotection reaction of the obtained N-tert-butoxycarbonylpipecolic acid amide derivative (VI) (step 3), followed by pipecolic acid amide derivative (VII) obtained in the third step in the presence of a base and an organic compound It can be obtained by a condensation reaction with an acid anhydride derivative (VIII) (the fourth step). The cyclic amine derivative (I) can also be obtained by condensation reaction of the pipecolic acid amide derivative (VII) with the organic acid ester derivative (IX). Moreover, cyclic amine derivative (I) can also be obtained by condensation reaction of pipecolic acid amide derivative (VII) and organic acid chloride derivative (X) in the presence of a base. In addition, cyclic amine derivative (I) can also be obtained by condensation reaction of pipecolic acid amide derivative (VII) and organic acid derivative (XI) in the presence of a condensing agent and a base. Moreover, cyclic amine derivative (I) can also be obtained by condensation reaction of pipecolic acid amide derivative (VII) and trimethylsilyl isocyanate in the presence of a base.

When cyclic amine derivative (I) contains, for example, an amino group, the amino group is converted to an amide group, a sulfonamide group, etc. or an N-alkyl compound by a condensation reaction or a reductive amination reaction, etc. May be Moreover, when it contains a sulfide group, the said sulfide group may be converted into a sulfonyl group by oxidation reaction. When an ester group is contained, the ester group may be converted to a carboxyl group by a hydrolysis reaction.

[Wherein, Q represents a halogen atom, and R ¹ to R ⁴ and X are as defined above. ]

(Step 1)
The amount of the halogenated aryl derivative (III) used for the coupling reaction is preferably 0.5 to 10 equivalents, more preferably 0.7 to 3 equivalents, to the boronic acid derivative (II).

Examples of the metal catalyst used for the coupling reaction include 1,1′-bis (diphenylphosphino) ferrocenedichloropalladium (II) dichloromethane adduct, palladium (II) chloride, bis (dibenzylideneacetone) palladium (0), Although tetrakistriphenyl phosphine palladium (0) or dichloro bis triphenyl phosphine palladium (0) is mentioned, 1,1'-bis (diphenyl phosphino) ferrocene dichloro palladium (II) dichloromethane adduct is preferred.

The amount of the metal catalyst used for the coupling reaction is preferably 0.01 to 5 equivalents, more preferably 0.05 to 0.5 equivalents, to the boronic acid derivative (II).

As a base used for the coupling reaction, for example, organic bases such as triethylamine or diisopropylethylamine, inorganic bases such as sodium carbonate or potassium carbonate, lithium amides such as lithium hexamethyl disilazide or lithium diisopropylamide, tert-butyloxy sodium Or a metal alkoxide such as tert-butyloxy potassium or a mixture thereof, but an inorganic base such as sodium carbonate or potassium carbonate is preferred.

The amount of the base used for the coupling reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents, to the boronic acid derivative (II).

The reaction solvent used for the coupling reaction is appropriately selected according to the type of reagent used, etc., and is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether or Ether solvents such as dimethoxyethane, nitrile solvents such as acetonitrile or propionitrile, aromatic hydrocarbon solvents such as benzene or toluene, aprotic polar solvents such as DMF or DMSO, water or mixed solvents thereof However, mixed solvents of nitrile solvents such as acetonitrile or propionitrile with water are preferred.

The reaction temperature of the coupling reaction is preferably 0 to 200 ° C., and more preferably 50 to 150 ° C.

The reaction time of the coupling reaction is appropriately selected according to the conditions such as the reaction temperature, but is preferably 1 to 30 hours.

The concentration at the start of the reaction of the boronic acid derivative (II) used for the coupling reaction is preferably 1 mmol / L to 1 mol / L.

The boronic acid derivative (II) and the halogenated aryl derivative (III) used for the coupling reaction can be purchased or can be prepared by known methods.

(Step 2)
The amount of pipecolic acid derivative (V) used for the condensation reaction is preferably 0.1 to 10 equivalents, and more preferably 0.5 to 3 equivalents with respect to biphenylamine derivative (IV).

Examples of the condensing agent used for the condensation reaction include N, N′-dicyclohexylcarbodiimide, N-ethyl-N′-3-dimethylaminopropylcarbodiimide hydrochloride, N, N′-carbodiimidazole, {{[(1- Cyano-2-ethoxy-2-oxoethylidene) amino] oxy} -4-morpholinomethylene} dimethylammonium hexafluorophosphate (hereinafter, COMU), O- (7-azabenzotriazol-1-yl) -1, 1,3,3-Tetramethyluronium hexafluorophosphate (hereinafter HATU) or O- (benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate ( Hereafter, although HBTU) is mentioned, HATU or HBTU is preferable.

The amount of the condensing agent used for the condensation reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents, with respect to the biphenylamine derivative (IV).

Examples of the base used for the condensation reaction include organic bases such as triethylamine or diisopropylethylamine, inorganic bases such as sodium hydrogencarbonate or potassium carbonate, sodium hydride, hydrogenated metal compounds such as potassium hydride or calcium hydride, methyl lithium Or an alkyllithium such as butyllithium, a lithium amide such as lithium hexamethyldisilazide or lithium diisopropylamide, or a mixture thereof, but an organic base such as triethylamine or diisopropylethylamine is preferred.

The amount of the base used for the condensation reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 5 equivalents based on the biphenylamine derivative (IV).

The biphenylamine derivative (IV) used for the condensation reaction may be a free form or a salt such as hydrochloride.

The reaction solvent used for the condensation reaction is appropriately selected according to the type of the reagent used, etc., but is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether or dimethoxymethane Ether solvents such as ethane, halogen solvents such as dichloromethane, chloroform or 1,2-dichloroethane, aprotic polar solvents such as DMF or DMSO, nitrile solvents such as acetonitrile or propionitrile, etc. may be mentioned. Halogenated solvents such as chloroform or 1,2-dichloroethane or aprotic polar solvents such as DMF or DMSO are preferred.

The reaction temperature of the condensation reaction is preferably 0 to 200 ° C., and more preferably 20 to 100 ° C.

The reaction time of the condensation reaction is appropriately selected depending on the conditions such as the reaction temperature, but is preferably 0.5 to 100 hours.

The concentration at the start of the reaction of the biphenylamine derivative (IV) used for the condensation reaction is preferably 1 mmol / L to 1 mol / L.

The pipecolic acid derivative (V) used for the condensation reaction can be purchased or can be produced by a known method or a method analogous thereto.

(Third step)
Examples of the acid used for the deprotection reaction include hydrochloric acid, trifluoroacetic acid or hydrofluoric acid, with hydrochloric acid or trifluoroacetic acid being preferred.

The amount of the acid used for the deprotection reaction is preferably 0.5 to 100 equivalents, more preferably 1 to 30 equivalents with respect to the N-tert-butoxycarbonylpipecolic acid amide derivative (VI).

The reaction solvent used for the deprotection reaction is appropriately selected according to the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction, and examples thereof include diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4- Ether solvents such as dioxane, ester solvents such as ethyl acetate or propyl acetate, chlorinated solvents such as dichloromethane, chloroform or 1,2-dichloroethane, alcohol solvents such as methanol or ethanol, aprotic such as DMF or DMSO Although polar solvents or mixed solvents thereof may be mentioned, halogen solvents such as dichloromethane, chloroform or 1,2-dichloroethane or aprotic polar solvents such as DMF or DMSO are preferable.

The reaction temperature of the deprotection reaction is preferably −78 ° C. to 200 ° C., and more preferably −20 ° C. to 100 ° C.

The reaction time of the deprotection reaction is appropriately selected depending on the conditions such as the reaction temperature, but is preferably 1 to 50 hours.

The concentration of the N-tert-butoxycarbonylpipecolic acid amide derivative (VI) used for the deprotection reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.

(Step 4)
The amount of the organic acid anhydride derivative (VIII), the organic acid ester derivative (IX), the organic acid chloride derivative (X), the organic acid derivative (XI) or trimethylsilyl isocyanate used for the condensation reaction is the pipecolic acid amide derivative (VII) Is preferably 1 to 200 equivalents, more preferably 1 to 80 equivalents.

As the condensing agent used for the condensation reaction, for example, N, N′-dicyclohexylcarbodiimide, N-ethyl-N′-3-dimethylaminopropylcarbodiimide hydrochloride, N, N′-carbodiimidazole, COMU, HATU or HBTU Of these, HATU or HBTU is preferred.

The amount of the condensing agent used for the condensation reaction is preferably 0 to 10 equivalents, more preferably 0 to 3 equivalents, relative to the pipecolic acid amide derivative (VII).

The amount of the base used for the condensation reaction is preferably 0 to 10 equivalents, more preferably 0 to 5 equivalents based on the pipecolic acid amide derivative (VII).

The pipecolic acid amide derivative (VII) used for the condensation reaction may be a free form or a salt such as hydrochloride.

The reaction solvent used for the condensation reaction is appropriately selected according to the type of the reagent used, etc., but is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether or dimethoxymethane Ether solvents such as ethane, chlorine solvents such as dichloromethane, chloroform or 1,2-dichloroethane, aprotic polar solvents such as DMF or DMSO, nitrile solvents such as acetonitrile or propionitrile, etc. may be mentioned. Halogenated solvents such as chloroform or 1,2-dichloroethane or aprotic polar solvents such as DMF or DMSO are preferred.

The reaction temperature of the condensation reaction is preferably -78 ° C to 200 ° C, and more preferably -20 ° C to 100 ° C.

The concentration of the pipecolic acid amide derivative (VII) used for the condensation reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.

Organic acid anhydride derivative (VIII), organic acid ester derivative (IX), organic acid chloride derivative (X), organic acid derivative (XI) and trimethylsilyl isocyanate used for condensation reaction can be purchased or known It can manufacture by a method or the method according to it.

The “RORγ antagonist” means a compound having the function of suppressing the function of RORγ to abolish or attenuate its activity.

"Inflammatory bowel disease" refers to a general term for diseases that cause chronic inflammation or ulceration in the mucosa of the large and small intestines, and mainly includes ulcerative colitis and Crohn's disease. Ulcerative colitis presents with bloody stools, mucous bloody stools, diarrhea or bloody diarrhea. In mild cases, bloody stools may be small and not accompanied by diarrhea, but in more severe cases, bloody diarrhea will result. Other symptoms may include abdominal pain, fever, loss of appetite, weight loss or anemia. Crohn's disease includes abdominal pain, diarrhea, weight loss, fever, or anal lesions. Intestinal obstruction, intestinal perforation or major hemorrhage may develop and may require surgery. Complications include lupus erythematosus, anemia, hypoproteinemia, ankylosing spondylitis, buccal aphthitis, erythema nodosa, pyoderma gangrenosum, iritis or growth disorder and the like.

Cyclic amine derivative (I) or a pharmacologically acceptable salt thereof, which is an active ingredient of the therapeutic or preventive agent for inflammatory bowel disease of the present invention, inhibits the binding of RORγ to a coactivator. It is characterized by suppressing the function of RORγ. Since RORγ is involved in the development of inflammatory bowel disease and disease progression, cyclic amine derivative (I) or a pharmacologically acceptable salt thereof suppresses inflammatory bowel disease by suppressing the function of RORγ. It can improve, cure or prevent.

It can be evaluated using in vitro tests that the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof has RORγ antagonist activity which inhibits the binding of RORγ to a coactivator. As an in vitro test, for example, a method of evaluating the binding of RORγ to an agonist (eg, cholesterol) (WO 2012/158784, WO 2013/018695), a ligand binding domain of RORγ and a coacti Methods for assessing binding to beta can be mentioned (WO 2012/064744, WO 2013/018695). In addition, the transcriptional activity inhibitory action of RORγ can be evaluated using various reporter gene assays (WO 2012/158784, WO 2012/064744, WO 2013/018695).

The fact that the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof suppresses the function of RORγ can produce IL-17 or Th17 using lymphocyte cells from various organs such as spleen or peripheral blood. Cell differentiation can be evaluated as an indicator. As a method using IL-17 production as an index, for example, a method of measuring IL-17 production by IL-23 stimulation using mouse splenocytes can be mentioned (The Journal of Biological Chemistry, 2003, 278) , No. 3, p. 1910-1914). As a method using Th17 cell differentiation as an index, for example, various cytokines (eg, IL-1β, IL-6, IL-23 and / or TGF are used, using CD4 positive naive T cells derived from mouse splenocytes or human PBMC). Stimulate with -β) and various antibodies (eg, anti-CD3 antibody, anti-CD28 antibody, anti-IL-4 antibody, anti-IFN-γ antibody and / or anti-IL-2 antibody) to differentiate to Th17 and produce IL-17 The method includes measuring the amount or the proportion of IL-17 positive cells etc. (WO 2012/158784, WO 2013/018695).

The effectiveness of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof for the treatment or prevention of inflammatory bowel disease can be evaluated using a pathological model. As a pathological condition model, for example, TNBS-induced colitis model (Europian Journal of Pharmacology, 2001, 431, p. 103-110), dextran sulfate sodium-induced colitis model (Laboratory Investigation, 1993, 69, p. .238-249), CD4-positive lymphocyte transfer colitis model (Gastroenterology, 2009, 136, p257-267), oxazolone-induced colitis model (Journal of Experimental Medicine, 1998, 188, p. 1929). -1939) or interleukin-10 deficient mice (Nature Genetics, 2008, 40, 1118-). 125) can be mentioned.

The efficacy of the cyclic amine derivative (I) or a pharmaceutically acceptable salt thereof for treating or preventing inflammatory bowel disease can be determined, for example, by using the above-mentioned in vitro test, for example, the ligand binding domain of RORγ and the coactivator. It is possible to evaluate the decrease in the amount of binding to E. coli or the decrease in the amount of IL-17 produced, which is an indicator of the function of RORγ, as an indicator. In addition, the efficacy for the treatment or prevention of inflammatory bowel disease should be evaluated, for example, using the TNBS-induced colitis model described above as a marker for the reduction of the gross injury score which is a characteristic indicator of inflammatory bowel disease. Can.

The cyclic amine derivative (I) or a pharmaceutically acceptable salt thereof is administered to mammals (eg, mice, rats, hamsters, rabbits, dogs, cats, monkeys, cattle, sheep or humans), particularly humans. When used, it can be used as a therapeutic or preventive agent for useful inflammatory bowel disease. When a cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is clinically used as a therapeutic or prophylactic agent for inflammatory bowel disease, the cyclic amine derivative (I) or a pharmacologically acceptable thereof is Salts, or pharmacologically acceptable carriers such as excipients, stabilizers, preservatives, buffers, solubilizers, solubilizers, emulsifiers, additives such as emulsifiers or diluents, etc. It can be mixed and administered orally or parenterally. In addition, the above-mentioned therapeutic agent or preventive agent for inflammatory bowel disease can be produced by a usual method using a carrier for these drugs as appropriate. The administration form of the above-mentioned therapeutic agent or preventive agent for inflammatory bowel disease may be, for example, tablets, capsules, granules, oral preparations such as powders or syrups, inhalants, noninjectives, injections, suppositories or liquids, etc. An ointment, a cream or a patch for oral administration or topical administration may be mentioned. Also, it may be a known sustained release preparation.

The therapeutic or preventive agent for the above-mentioned inflammatory bowel disease preferably contains 0.00001 to 90% by weight of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof, preferably 0.01 to 70%. It is more preferable to contain%. The dose is appropriately selected according to the patient's condition, age and body weight, and administration method, but as an active ingredient amount for adults, 0.1 μg to 1 g per day for injections and 1 for oral preparations 1 μg to 10 g per day, 1 μg to 10 g per day for patches, 1 μg to 10 g per day for ointments, 1 μg to 10 g per day for creams, each once or several times It can be divided and administered.

Examples of pharmacologically acceptable carriers or diluents for the above-mentioned therapeutic or preventive agent for inflammatory bowel disease include binders (syrup, gelatin, gum arabic, sorbitol, polyvinyl chloride or tragacanth, etc.), excipients, etc. The agents (sugar, lactose, corn starch, calcium phosphate, sorbitol or glycine etc.) or lubricants (magnesium stearate, polyethylene glycol, talc or silica etc.) may be mentioned.

The above-mentioned therapeutic agent or preventive agent for inflammatory bowel disease may be used in combination with or in combination with other agents in an appropriate amount in order to supplement or enhance its therapeutic or preventive effect or to reduce its dose.

The present invention will be described in more detail by the following reference examples and examples, but the present invention is not limited thereto.

The compounds used for the synthesis of the compounds of Reference Examples and Examples were commercially available compounds that were not described in the synthesis method. The “room temperature” in the following Reference Examples and Examples usually indicates about 10 ° C. to about 35 ° C. % Indicates mol / mol% for yield, volume% for solvents used in column chromatography and high performance liquid chromatography, and weight% unless otherwise specified. The solvent name shown in the NMR data indicates the solvent used for the measurement. The 400 MHz NMR spectrum was measured using a JNM-AL400 nuclear magnetic resonance apparatus (Nippon Electron Ltd.) or a JNM-ECS400 nuclear magnetic resonance apparatus (Nippon Denshi Co., Ltd.). Chemical shifts are expressed in δ (unit: ppm) relative to tetramethylsilane, and signals are s (singlet), d (doublet), t (triplet), q (quadruple), quint respectively (Quaternion), sept (seven), m (multiple), br (wide), dd (double double), dt (double triple), ddd (double double) , Dq (double quadruple), td (triple doublet), tt (triple triple). When protons such as a hydroxyl group and an amino group are very mild peaks, they are not described. The ESI-MS spectrum was measured using Agilent Technologies 1200 Series, G6130A (Agilent Technologies). Silica gel used silica gel 60 (Merck), amine silica gel used amine silica gel DM 1020 (Fuji Silysia Chemical Ltd.), and chromatography used YFLC W-prep 2 XY (Yamazen Co., Ltd.).

(Reference Example 1) Synthesis of 2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-amine:

To a solution of 2-trifluoromethoxyphenylboronic acid (1.10 g, 5.33 mmol) in acetonitrile (9.0 mL) was added 4-bromo-3-chloroaniline (1.00 g, 4.84 mmol), potassium carbonate (1. 10 g, 4.84 mmol). 00 g, 7.27 mmol), 1,1′-bis (diphenylphosphino) ferrocene dichloropalladium (II) dichloromethane adduct (0.396 g, 0.484 mmol) and distilled water (3.0 mL) are added at room temperature, 90 After the temperature was raised to ° C, the mixture was stirred for 18 hours. The reaction solution was filtered through silica gel, and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 85 / 15-67 / 33) and 2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4 An amine (hereinafter, the compound of Reference Example 1) (1.03 g, 3.57 mmol, 73.6%) was obtained as a yellow oil.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 3.79 (s, 2 H), 6.62 (dd, J = 8.3, 2.3 Hz, 1 H), 6.80 (d, J = 2. 3 Hz, 1 H), 7.05 (d, J = 8.3 Hz, 1 H), 7.30 to 7.41 (m, 4 H).
ESI-MS: m / z = 288 (M + H) ⁺ .

Reference Example 2 Synthesis of tert-butyl 2-((2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) carbamoyl) piperidine-1-carboxylic acid:

In a solution of 1- (tert-butoxycarbonyl) piperidine-2-carboxylic acid (0.263 g, 1.15 mmol) in DMF (2.0 mL), the compound of Reference Example 1 (0.300 g, 1.04 mmol) in DMF (0.300 g, 1.04 mmol) was added. 2.0 mL) solution, HATU (0.436 g, 1.15 mmol) and diisopropylethylamine (0.273 mL, 1.56 mmol) were added at room temperature and stirred at the same temperature for 16 hours. Distilled water was added to the reaction mixture, and the mixture was extracted with a mixed solvent of n-hexane / ethyl acetate = 20/80 (v / v). The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 90/10 to 67/33) to give 2-((2-chloro-2 '-(trifluoromethoxy)-[1,1'- Biphenyl] -4-yl) carbamoyl) piperidine-1-carboxylic acid tert-butyl (hereinafter compound of Reference Example 2) (0.483 g, 0.968 mmol, 92.8%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.43-1.51 (m, 2 H), 1.53 (s, 9 H), 1.60-1. 75 (m, 3 H), 2.35 (D, J = 12.7 Hz, 1 H), 2.80-2.89 (m, 1 H), 4.03-4. 13 (m, 1 H), 4.86-4. 89 (m, 1 H) , 7.22 (d, J = 8.3 Hz, 1 H), 7. 29-7. 45 (m, 6 H), 7. 80 (br, 1 H).
ESI-MS: m / z = 499 (M + H) ^<+> .

Reference Example 3 Synthesis of N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide:

To a solution of the compound of Reference Example 2 (0.483 g, 0.968 mmol) in dichloromethane (5.0 mL) was added trifluoroacetic acid (0.522 mL, 6.78 mmol) at room temperature, and the mixture was stirred at the same temperature for 20 hours. The reaction mixture was concentrated under reduced pressure, aqueous potassium carbonate solution was added to neutralize, and then extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (amine silica gel, n-hexane / ethyl acetate = 60/40 to 20/80) to give N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'- Biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Reference Example 3) (0.309 g, 0.775 mmol, 80.0%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.53 (ddd, J = 36.8, 17.9, 8.8 Hz, 4 H), 1.78-1.86 (m, 1 H), 00-2.07 (m, 1 H), 2.74-2.82 (m, 1 H), 3.03-3.10 (m, 1 H), 3.38 (dd, J = 9.6, 3) .5 Hz, 1 H), 7.23 (d, J = 8.3 Hz, 1 H), 7.31-7. 37 (m, 3 H), 7.40-7.45 (m, 1 H), 7.53 (Dd, J = 8.3, 2.0 Hz, 1 H), 7.82 (d, J = 2.2 Hz, 1 H), 9.02 (br, 1 H).
ESI-MS: m / z = 399 (M + H) ^<+> .

Example 1 Synthesis of 1-Acetyl-N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide:

Triethylamine (0.0367 mL, 0.263 mmol) and acetic anhydride (0.0182 mL, 0.193 mmol) in dichloromethane (3.0 mL) solution of the compound of Reference Example 3 (0.0700 g, 0.176 mmol) at 0 ° C. In addition, the mixture was heated to room temperature and stirred for 1 hour. Distilled water was added to the reaction solution, and extracted with chloroform. The organic layer was washed with distilled water and saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, chloroform / methanol = 95/5) to give 1-acetyl-N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4. -Yl) piperidine-2-carboxamide (hereinafter, the compound of Example 1) (0.0730 g, 0.166 mmol, 94.3%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.63 (m, 1 H), 1.67 (d, J = 7.8 Hz, 1 H), 1.89 to 2.02 (m, 1) 2H), 2.22 (s, 3H), 2.29 (d, J = 12.9 Hz, 1 H), 3.22 (t, J = 13.2 Hz, 1 H), 3.78 (d, J = 12.7 Hz, 1 H), 5. 29 (d, J = 5.1 Hz, 1 H), 7. 20 (d, J = 8.3 Hz, 1 H), 7. 29-7. 37 (m, 3 H), 7.40-7.44 (m, 2H), 7.80 (br, 1 H), 8.65 (br, 1 H).
ESI-MS: m / z = 441 (M + H) ⁺ .

Example 2 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2,2,2-trifluoroacetyl) piperidine Synthesis of 2-carboxamide:

N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] in the same manner as in Example 1 except for using trifluoroacetic anhydride instead of acetic anhydride 4-yl) -1- (2,2,2-trifluoroacetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 2) (0.0500 g, 0.101 mmol, 99.0%) as a white solid Got as.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.56-1.86 (m, 4 H), 1.98 (dt, J = 11.2, 4.6 Hz, 1 H), 2.36 (d, J = 14.1 Hz, 1 H), 3.37 (td, J = 13.4, 2.6 Hz, 1 H), 4.01 (d, J = 13.9 Hz, 1 H), 5.18 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.30 to 7.46 (m, 5 H), 7.79 (br, 1 H), 7.89 (br) , 1 H).
ESI-MS: m / z = 495 (M + H) ^<+> .

Example 3 Synthesis of N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1-propionylpiperidine-2-carboxamide:

Triethylamine (0.0157 mL, 0.113 mmol) and propionyl chloride (0.00719 mL, 0.0828 mmol) in a solution of the compound of Reference Example 3 (0.0300 g, 0.0752 mmol) in dichloromethane (2.0 mL) at 0 ° C. In addition, the mixture was heated to room temperature and stirred for 30 minutes. Methanol was added to the reaction solution and concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, chloroform / methanol = 100/0 to 90/10) to give N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4. -Yl) -1-propionylpiperidine-2-carboxamide (hereinafter, the compound of Example 3) (0.0340 g, 0.0747 mmol, 99.4%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.22 (t, J = 7.3 Hz, 3 H), 1.55 (br, 2 H), 1.76 (br, 2 H), 1.97 (t , J = 13.2 Hz, 1H), 2.30 (d, J = 12.7 Hz, 1 H), 2.48 (dq, J = 6.6, 2.0 Hz, 2 H), 3.12 (td, t) J = 13.2, 2.8 Hz, 1H), 3.83 (d, J = 13.2 Hz, 1 H), 5.29 (d, J = 5.4 Hz, 1 H), 7.20 (d, J = 8.3 Hz, 1 H), 7. 29-7. 36 (m, 4 H), 7. 39-7. 45 (m, 1 H), 7.8 4 (br, 1 H), 8.5 6 (br, 1 H) ).
ESI-MS: m / z = 455 (M + H) ⁺ .

Example 4 Synthesis of N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2-methoxyacetyl) piperidine-2-carboxamide :

A solution of the compound of Reference Example 3 (0.0300 g, 0.0752 mmol) in DMF (0.5 mL) in a solution of 2-methoxyacetic acid (0.00693 ml, 0.0903 mmol) in DMF (0.5 mL), HATU (0. 0343 g (0.0902 mmol) and diisopropylethylamine (0.0197 mL, 0.113 mmol) were added at room temperature and stirred at the same temperature for 3 hours. Distilled water was added to the reaction liquid, and extracted with a mixed solvent of n-hexane / ethyl acetate = 20/80. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 50/50 to 0/100) to give N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl ] 4-yl) -1- (2-methoxyacetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 4) (0.0266 g, 0.0565 mmol, 74.6%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.58-2.00 (m, 5 H), 2. 33 (d, J = 14.4 Hz, 0.8 H), 2.48 (d, J = 12.7 Hz, 0.2 H), 2.63 (t, J = 12.7 Hz, 0.2 H), 3.14 (t, J = 13.0 Hz, 0.8 H), 3.48 (s, 2) .4 H), 3.51 (s, 0.6 H), 3.82 (d, J = 12.7 Hz, 0.8 H), 4.12 (d, J = 11.7 Hz, 0.2 H), 4 .18 (d, J = 13.9 Hz, 0.8 H), 4.26 (d, J = 13.9 Hz, 0.8 H), 4. 34 (d, J = 11.7 Hz, 0.2 H), 4.52-4.60 (m, 0.2 H), 4.64-4.68 (m, 0.2 H), 5.23 (d, J = 6.1 Hz, 0.8 H), 7.20 (D, J = 8.3 H , 1H), 7.28-7.45 (m, 5H), 7.65-7.90 (m, 1H), 8.46 (br, 0.8H), 8.57 (br, 0.2H) ).
ESI-MS: m / z = 471 (M + H) ^<+> .

Example 5 Synthesis of N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2-hydroxyacetyl) piperidine-2-carboxamide :

N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl]-was carried out according to the same procedure as in Example 4 except that glycolic acid was used instead of 2-methoxyacetic acid. 4-yl) -1- (2-hydroxyacetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 5) (0.0114 g, 0.0250 mmol, 33.2%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48-1.55 (m, 1 H), 1.63-1.71 (m, 1 H), 1.75-1. 85 (m, 2 H) , 1. 91-2. 02 (m, 1 H), 2. 32 (d, J = 1 3.4 Hz, 1 H), 3.17-3. 25 (m, 1 H), 3.43-3. 53 ( m, 2H), 4.28-4. 32 (m, 2H), 5. 26 (d, J = 5.6 Hz, 1 H), 7.22 (d, J = 8.3 Hz, 1 H), 7. 30-7.45 (m, 5 H), 7.77 (br, 1 H), 8. 14 (br, 1 H).
ESI-MS: m / z = 457 (M + H) ^<+> .

Example 6 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (dimethylamino) acetyl) piperidine-2- Carboxamide Synthesis:

The procedure is as in Example 4 except that N, N-dimethylglycine hydrochloride is used instead of 2-methoxyacetic acid, and N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1 is obtained by the same procedure as in Example 4. 1′-biphenyl] -4-yl) -1- (2- (dimethylamino) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 6) (0.0273 g, 0.0564 mmol, 90.0%) Was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.40-2.20 (m, 6 H), 2.34 (s, 3 H), 2.47-2.50 (m, 3.4 H), 2 .56-2.64 (m, 0.4 H), 2.92 (d, J = 12.6 Hz, 0.6 H), 3.06-3.14 (m, 0.4 H), 3.24 ( s, 0.6 H), 3.67 (d, J = 12.6 Hz, 0.6 H), 4.03-4.07 (m, 0.4 H), 4.54-4.62 (m, 1 .2H), 5.24-5.27 (m, 0.4 H), 7.19-7.23 (m, 1 H), 7.30-7.46 (m, 5 H), 7.73-7 .75 (m, 1 H), 8.53 (br, 0.4 H), 10. 69 (br, 0.6 H).
ESI-MS: m / z = 484 (M + H) ⁺ .

Example 7 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2,2-difluoroacetyl) piperidine-2-carboxamide Composition of:

N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl]-was carried out according to the same procedure as in Example 4 except for using difluoroacetic acid instead of 2-methoxyacetic acid. 4-yl) -1- (2,2-difluoroacetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 7) (0.0212 g, 0.0444 mmol, 59.1%) was obtained as a white solid.
¹ H-NMR (400 MHz, DMSO-D ₆ ) δ: 1.40-1.80 (m, 5.0 H), 2.21-2.24 (m, 0.7 H), 2.29-2. 34 (m, 0.3 H), 2.65-2.68 (m, 0.3 H), 3.46-3. 55 (m, 0.7 H), 3.82-3. 88 (m, 0) .7H), 4.28-4.34 (m, 0.3 H), 4.79-4.81 (m, 0.3 H), 5.07-5. 10 (m, 0.7 H), 6 .73 (t, J = 52.6 Hz, 0.3 H), 6.83 (t, J = 52.7 Hz, 0.7 H), 7.32 (d, J = 8.3 Hz, 1 H), 7. 39-7.43 (m, 1H), 7.45-7.51 (m, 2H), 7.53-7.60 (m, 2H), 7.90-7.93 (m, 1H), 10.19 (br, 0.3 H), 10.2 (Br, 0.7H).
ESI-MS: m / z = 477 (M + H) ⁺ .

Example 8 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (trifluoromethoxy) acetyl) piperidine-2 -Synthesis of carboxamide:

The procedure is as in Example 4 except that 2-trifluoromethoxyacetic acid is used instead of 2-methoxyacetic acid, and N- (2-chloro-2 '-(trifluoromethoxy)-[1,1' -Biphenyl] -4-yl) -1- (2- (trifluoromethoxy) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 8) (0.00890 g, 0.0170 mmol, 16.9%) Obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.55-1. 71 (m, 2 H), 1.76-1.84 (m, 2 H), 1.94-2.03 (m, 1 H) , 2.32 (d, J = 14.5 Hz, 1 H), 3. 29 (td, J = 13.1, 2.7 Hz, 1 H), 3.67 (d, J = 12.7 Hz, 1 H), 4.68-4.76 (m, 2 H), 5.22 (d, J = 5.4 Hz, 1 H), 7.21-7. 45 (m, 6 H), 7.81 (br, 1 H), 8.26 (s, 1 H).
ESI-MS: m / z = 523 (M-H) ^- .

Reference Example 4 (2- (2-((2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -2- Synthesis of tert-butyl oxoethyl) carbamate:

A procedure similar to that of Example 4 is used except that 2-((tert-butoxycarbonyl) amino) acetic acid is used instead of 2-methoxyacetic acid to give (2- (2-((2-chloro-2′- (Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -2-oxoethyl) carbamic acid tert-butyl (hereinafter compound of Reference Example 4) (0.116 g , 0.208 mmol, quantitative) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 (s, 9 H), 1.45-1. 90 (m, 5 H), 2.38 (d, J = 13.2 Hz, 1 H), 3 .21 (t, J = 12.1 Hz, 1 H), 3.75 (d, J = 13.9 Hz, 1 H), 3.95 (dd, J = 16.7, 5.0 Hz, 1 H); 09-4.15 (m, 1 H), 5.32 (d, J = 4.9 Hz, 1 H), 5.42 (br, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.29-7.36 (m, 3 H), 7.40-7. 45 (m, 1 H), 7.52 (br, 1 H), 7. 80 (br, 1 H), 8.31 (br, 1H).
ESI-MS: m / z = 556 (M + H) ⁺ .

Reference Example 5 Synthesis of 1- (2-aminoacetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide :

To a solution of the compound of Reference Example 4 (0.115 g, 0.207 mmol) in dichloromethane (1.0 mL) was added trifluoroacetic acid (0.112 mL, 1.45 mmol) at room temperature, and the mixture was stirred at the same temperature for 15 hours. The reaction mixture was concentrated under reduced pressure, aqueous potassium carbonate solution was added to neutralize, and then extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (amine silica gel, chloroform / methanol = 100/0 to 96/4) to give 1- (2-aminoacetyl) -N- (2-chloro-2 '-(trifluoromethoxy)- [1,1′-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Reference Example 5) (0.0613 g, 0.134 mmol, 65.0%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.45-1.63 (m, 2 H), 1.70-1.81 (m, 2 H), 1.89-1.99 (m, 1 H) , 2.31 (d, J = 14.0 Hz, 1 H), 3.16 (td, J = 14.0, 2.3 Hz, 1 H), 3.60 (d, J = 1.0 Hz, 2 H), 3.68 (d, J = 14.0 Hz, 1 H), 5. 27 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.30-7 45 (m, 5 H), 7.77 (br, 1 H), 8.39 (br, 1 H).
ESI-MS: m / z = 456 (M + H) ⁺ .

Reference Example 6 (2- (2-((2-Chloro-2 '-(trifluoromethoxy)-[1, 1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -2- Synthesis of tert-butyl oxoethyl) (methyl) carbamate:

A procedure similar to that of Example 4 is used except that N- (tert-butoxycarbonyl) -N-methylglycine is used instead of 2-methoxyacetic acid to give (2- (2-((2-chloro-2 ′) -(Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -2-oxoethyl) (methyl) carbamic acid tert-butyl (hereinafter, the compound of Reference Example 6) (0.132 g, 0.232 mmol, 92.6%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.57 (s, 9 H), 1.38-1.80 (m, 5 H), 2.46-2.53 (m, 1 H), 3.05 (S, 3 H), 3.15-3. 22 (m, 1 H), 3. 66 (d, J = 15.7 Hz, 1 H), 3.77-3. 84 (m, 1 H), 4.41 (D, J = 15.7 Hz, 1 H), 5.41-5. 44 (m, 1 H), 7.19 (d, J = 8.3 Hz, 1 H), 7.28-7. 4 (m, 1 H) 4H), 7.70 (br, 1 H), 7.88 (br, 1 H), 8.61 (br, 1 H).
ESI-MS: m / z = 571 (M + H) ⁺ .

Example 9 Synthesis of 1- (2-acetamidoacetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide :

According to the same procedure as in Example 3 except for using the compound of Reference Example 5 in place of the compound of Reference Example 3 and acetyl chloride instead of propionyl chloride, 1- (2-acetamidoacetyl) -N- ( 2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 9) (0.0274 g, 0.0550 mmol, 80) .9%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.90 (m, 5 H), 2.09 (s, 3 H), 2.37 (d, J = 14.4 Hz, 1 H), 3 .25 (td, J = 13.0, 2.4 Hz, 1 H), 3.75 (d, J = 12.4 Hz, 1 H), 4.11 (dd, J = 17.2, 4.0 Hz, 1 H ), 4.21 (dd, J = 17.2, 4.0 Hz, 1 H), 5. 29 (d, J = 5.1 Hz, 1 H), 6.53 (br, 1 H), 7.21 (d , J = 8.5 Hz, 1 H), 7.29-7.37 (m, 3 H), 7.40-7.48 (m, 2 H), 7. 80 (br, 1 H), 8.26 (br) , 1 H).
ESI-MS: m / z = 498 (M + H) ⁺ .

Example 10 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (methylsulfonamido) acetyl) piperidine-2 -Synthesis of carboxamide:

N- (2-chloro-2 ′-(N- (2-chloro-2 ′-()) by the same procedure as in Example 3 except for using the compound of Reference Example 5 in place of the compound of Reference Example 3 and methanesulfonyl chloride in place of Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (methylsulfonamido) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 10) (0.0202 g, 0.0378 mmol, 79.2%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.52-1.95 (m, 5 H), 2. 32 (d, J = 14.1 Hz, 1 H), 3.02 (s, 3 H), 3 .33 (t, J = 12.8 Hz, 1 H), 3.64 (d, J = 13.0 Hz, 1 H), 4.08 (d, J = 4.6 Hz, 2 H), 5.25 (d, J = 4.6 Hz, 1 H), 5.48 (br, 1 H), 7.22 (d, J = 8.3 Hz, 1 H), 7.29-7.45 (m, 5 H), 7.81 ( br, 1 H), 8.09 (br, 1 H).
ESI-MS: m / z = 534 (M + H) ^<+> .

Example 11 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (methylamino) acetyl) piperidine-2- Carboxamide Synthesis:

N- (2-chloro-2 '-(trifluoromethoxy)-[1,1' was prepared according to the same procedure as in Reference Example 5 except for using the compound of Reference Example 6 in place of the compound of Reference Example 4. -Biphenyl] -4-yl) -1- (2- (methylamino) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 11) (0.0799 g, 0.170 mmol, 73.4%) with a white color Obtained as a solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.26 to 1.76 (m, 5 H), 1.90 to 2.06 (m, 1 H), 2.28 to 2.42 (m, 1 H) , 2.50 (s, 2.4 H), 2.60-2.63 (m, 0.8 H), 3.15 (t, J = 12.2 Hz, 0.8 H), 3.43 (d, J = 12.7 Hz, 0.2 H), 3.52 (s, 1.6 H), 3.70 to 3.76 (m, 1 H), 4.58 to 4.63 (m, 0.4 H), 5.28 (d, J = 4.9 Hz, 0.8 H), 7.19-7.23 (m, 1 H), 7.30-7.45 (m, 5 H), 7.75-7.77 (M, 1 H), 8.44 (s, 0.8 H), 10. 49 (s, 0.2 H).
ESI-MS: m / z = 470 (M + H) ⁺ .

Example 12 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (N-methylacetamido) acetyl) piperidine Synthesis of 2-carboxamide:

N- (2-chloro-2 '-(tri) by the same procedure as in Example 3 except for using the compound of Example 11 in place of the compound of Reference Example 3 and acetyl chloride in place of propionyl chloride Fluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (N-methylacetamido) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 12) (0.0261 g, 0.0510 mmol, 95.8%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48-1.76 (m, 5 H), 2.20 (s, 3 H), 2.50-2.65 (m, 1 H), 3.24 (S, 2.1 H), 3.30 (s, 0.9 H), 3.20-3. 31 (m, 1 H), 3.34 (d, J = 15.0 Hz, 0.3 H), 3 4.63 (d, J = 15.0 Hz, 0.7 H), 3.83-3.89 (m, 0.7 H), 4.60 (d, J = 15.0 Hz, 0.7 H), 4. 64-4. 70 (m, 0.6 H), 4.78 (d, J = 15.0 Hz, 0.3 H), 5.41 (d, J = 4.5 Hz, 0.7 H), 7.20 -7.22 (m, 1 H), 7.30-7.35 (m, 3 H), 7.39-7.44 (m, 1 H), 7.60-7.75 (m, 0.7 H) , 7.77 (dd, J = 8.4, .0 Hz, 0.3 H), 7.98-8.07 (m, 0.7 H), 8. 14 (d, J = 1.8 Hz, 0.3 H), 8.64 (br, 0.7 H) , 9.63 (br, 0.3 H).
ESI-MS: m / z = 512 (M + H) ⁺ .

Example 13 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfonamido) acetyl) Synthesis of piperidine-2-carboxamide:

N- (2-chloro-2 ′-(N- (2-chloro-2 ′-()) by a procedure similar to that of Example 3 except that the compound of Example 11 is used instead of the compound of Reference Example 3 and methanesulfonyl chloride is used instead of propionyl chloride. Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 13) (0 0.264 g, 0.0482 mmol, 90.6%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.52-1.89 (m, 5 H), 2.35-2.38 (m, 1 H), 3.03-3. 07 (m, 6 H) , 3.20-3.31 (m, 1 H), 3.67-3. 76 (m, 1 H), 4.16-4. 27 (m, 2 H), 5.25-5. 26 (m, 1H), 7.21-7.23 (m, 1H), 7.30-7.45 (m, 5H), 7.83 (s, 1H), 8.22 (br, 1H).
ESI-MS: m / z = 548 (M + H) ^<+> .

Example 14 Synthesis of N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (ethylsulfonyl) piperidine-2-carboxamide:

N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4 by the same procedure as in Example 3 except for using ethanesulfonyl chloride instead of propionyl chloride -Yl) -1- (ethylsulfonyl) piperidine-2-carboxamide (hereinafter compound of Example 14) (0.0660 g, 0.134 mmol, 99.3%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.47 (t, J = 7.4 Hz, 3 H), 1.58-1.68 (m, 2 H), 1.69-1.84 (m, 3H), 2.59 (d, J = 12.4 Hz, 1 H), 3.06-3.21 (m, 4 H), 3.88 (d, J = 1 2.0 Hz, 1 H), 4.56 ( d, J = 8.3 Hz, 1 H), 7.24 (d, J = 8.3 Hz, 1 H), 7.31-7. 38 (m, 3 H), 7.47-7. 50 (m, 2 H) ), 7.85 (s, 1 H), 8.53 (br, 1 H).
ESI-MS: m / z = 491 (M + H) ⁺ .

Example 15 Synthesis of N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (methylsulfonyl) piperidine-2-carboxamide:

N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4 by the same procedure as in Example 3 except that methanesulfonyl chloride is used instead of propionyl chloride. -Yl) -1- (methylsulfonyl) piperidine-2-carboxamide (hereinafter, the compound of Example 15) (0.0800 g, 0.168 mmol, 66.9%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.47-1.61 (m, 1 H), 1.62-1.81 (m, 4 H), 2.45 (d, J = 10.4 Hz, 1H), 3.04 (s, 3 H), 3.23 (td, J = 13.3, 2.4 Hz, 1 H), 3.93 (t, J = 7.0 Hz, 1 H), 4.64 (4) br, 1 H), 7. 25 (d, J = 8.5 Hz, 1 H), 7.30-7. 38 (m, 3 H), 7.43 (dt, J = 10.8, 3.7 Hz, 2 H ), 7.84 (d, J = 2.2 Hz, 1 H), 8. 29 (br, 1 H).
ESI-MS: m / z = 477 (M + H) ⁺ .

Example 16 Synthesis of N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1-formylpiperidine-2-carboxamide:

Ethyl formate (0.567 mL, 7.02 mmol) is added to a solution of the compound of Reference Example 3 (0.0400 g, 0.100 mmol) in dichloromethane (1.0 mL) at 0 ° C., and the temperature is raised to 90 ° C. for 18 hours It stirred. The reaction solution is concentrated under reduced pressure, and the residue is purified by column chromatography (silica gel, chloroform / methanol = 100/0 to 90/10) to give N- (2-chloro-2 '-(trifluoromethoxy)-[1,1. 1′-biphenyl] -4-yl) -1-formylpiperidine-2-carboxamide (hereinafter, the compound of Example 16) (0.0300 g, 0.0703 mmol, 70.1%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.42-1.64 (m, 2H), 1.82 (d, J = 10.0 Hz, 2H), 1.95 (dt, J = 8. 8, 4.3 Hz, 1 H), 2. 35 (d, J = 13.9 Hz, 1 H), 3. 29 (td, J = 13.2, 2.8 Hz, 1 H), 3.63 (d, J = 9.5 Hz, 1 H), 5.12 (d, J = 5.6 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.28-7.45 (m, 5 H) , 7.80 (br, 1 H), 8.21 (d, J = 9.2 Hz, 1 H), 8.32 (br, 1 H).
ESI-MS: m / z = 427 (M + H) ⁺ .

(Example ¹⁷⁾ N 2 - (2-chloro-2 '- (trifluoromethoxy) - [1,1'-biphenyl] -4-yl) piperidine-1,2-dicarboxamide:

Trimethylsilyl isocyanate (0.0333 mL, 0.251 mmol) and triethylamine (0.0349 mL, 0.251 mmol) were added to a solution of the compound of Reference Example 3 (0. 100 g, 0.251 mmol) in dichloromethane (3.0 mL) at 0 ° C. The mixture was stirred for 72 hours after the temperature was raised to room temperature. Methanol was added to the reaction solution and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, chloroform) to ^obtain, N 2 - (2-chloro-2 '- (trifluoromethoxy) - [1,1'-biphenyl] -4-yl) piperidine-1,2 Dicarboxamide (hereinafter, the compound of Example 17) (0.0300 g, 0.0679 mmol, 27.1%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.68 (m, 2H), 1.73 (br, 2H), 1.81-1.92 (m, 1H), 2.30 (D, J = 12.9 Hz, 1 H), 3.21 (dt, J = 12.8, 2.6 Hz, 1 H), 3.52 (d, J = 13.2 Hz, 1 H), 4.81 (d br, 2H), 5.03 (d, J = 4.6 Hz, 1 H), 7.20 (d, J = 8.3 Hz, 1 H), 7.29-7.37 (m, 3 H), 7. 42 (dt, J = 10.8, 3.8 Hz, 2 H), 7.81 (br, 1 H), 8.95 (br, 1 H).
ESI-MS: m / z = 442 (M + H) ⁺ .

(Example ¹⁸⁾ N 2 - (2-chloro-2 '- (trifluoromethoxy) - [1,1'-biphenyl] ^-4-yl) -N 1, ^{N 1} - dimethylpiperidine-1,2 Carboxamide Synthesis:

Using propionyl chloride dimethylcarbamoyl chloride in place of chloride, by the same procedure otherwise as in Example 3, N 2 ^- (2-chloro-2 '- (trifluoromethoxy) - [1,1'-biphenyl] - 4-yl) -N ¹ , N ¹ -dimethylpiperidine-1,2-dicarboxamide (hereinafter, the compound of Example 18) (0.0231 g, 0.0492 mmol, 65.4%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48-1 to 78 (m, 4 H), 1.92 to 2. 05 (m, 1 H), 2.27 to 2. 35 (m, 1 H) , 2.94 (s, 6 H), 2.87-2.99 (m, 1 H), 3.40-3. 46 (m, 1 H), 4.47-4. 51 (m, 1 H), 7 20 (d, J = 8.6 Hz, 1 H), 7.30-8.00 (m, 6 H), 10. 60 (br, 1 H).
ESI-MS: m / z = 470 (M + H) ⁺ .

Example 19 Synthesis of methyl 2-((2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) carbamoyl) piperidine-1-carboxylate:

2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] by the same procedure as in Example 3 except for using methyl chloroformate instead of propionyl chloride Methyl 4-yl) carbamoyl) piperidine-1-carboxylate (hereinafter, the compound of Example 19) (0.0316 g, 0.0692 mmol, 92.0%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46-1.78 (m, 5 H), 2.30-2.41 (m, 1 H), 2.92 (t, J = 12.1 Hz, 1H), 3.81 (s, 3H), 4.05-4.20 (br, 1H), 4.93 (d, J = 4.6 Hz, 1H), 7.23 (d, J = 8. 5 Hz, 1 H), 7.31-7. 45 (m, 5 H), 7.74-7. 86 (m, 1 H), 8.21 (br, 1 H).
ESI-MS: m / z = 457 (M + H) ^<+> .

Reference Example 7 (R) -2-((2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) carbamoyl) piperidine-1-carboxylic acid tert-butyl Composition of:

The compound of Reference Example 1 (1.05 g, 3) was added to a solution of (R)-(+)-1- (tert-butoxycarbonyl) piperidine-2-carboxylic acid (0.840 g, 3.66 mmol) in DMF (18 mL). .66 mmol), HATU (1.53 g, 4.03 mmol) and diisopropylethylamine (0.768 mL, 4.40 mmol) were added at room temperature and stirred at the same temperature for 18 hours. Distilled water was added to the reaction solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 80/20) to give (R) -2-((2-chloro-2 '-(trifluoromethoxy)-[1,1'- Biphenyl] -4-yl) carbamoyl) piperidine-1-carboxylic acid tert-butyl (hereinafter, the compound of Reference Example 7) (1.60 g, 3.20 mmol, 87.3%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.43-1.51 (m, 2 H), 1.53 (s, 9 H), 1.60-1. 75 (m, 3 H), 2.35 (D, J = 12.7 Hz, 1 H), 2.80-2.89 (m, 1 H), 4.03-4. 13 (m, 1 H), 4.86-4. 89 (m, 1 H) , 7.22 (d, J = 8.3 Hz, 1 H), 7. 29-7. 45 (m, 6 H), 7. 80 (br, 1 H).
ESI-MS: m / z = 499 (M + H) ^<+> .

Reference Example 8 Synthesis of (R) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide:

To a solution of the compound of Reference Example 7 (1.60 g, 3.21 mmol) in dichloromethane (30 mL) was added trifluoroacetic acid (8.02 mL, 104 mmol) at room temperature, and the mixture was stirred at the same temperature for 2 hours. Distilled water was added to the reaction solution, and extracted with chloroform. The aqueous layer was neutralized with 1 M aqueous sodium hydroxide solution, and extracted with chloroform. The organic layer is washed with distilled water and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give (R) -N- (2-chloro-2 '-(trifluoromethoxy)-[ 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Reference Example 8) (1.13 g, 2.84 mmol, 88.6%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.53 (ddd, J = 36.8, 17.9, 8.8 Hz, 4 H), 1.78-1.86 (m, 1 H), 00-2.07 (m, 1 H), 2.74-2.82 (m, 1 H), 3.03-3.10 (m, 1 H), 3.38 (dd, J = 9.6, 3) .5 Hz, 1 H), 7.23 (d, J = 8.3 Hz, 1 H), 7.31-7. 37 (m, 3 H), 7.40-7.45 (m, 1 H), 7.53 (Dd, J = 8.3, 2.0 Hz, 1 H), 7.82 (d, J = 2.2 Hz, 1 H), 9.02 (br, 1 H).
ESI-MS: m / z = 399 (M + H) ^<+> .

Example 20 Synthesis of (R) -1-acetyl-N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide:

To a solution of the compound of Reference Example 8 (1.43 g, 3.59 mmol) in dichloromethane (36 mL) was added triethylamine (0.750 mL, 5.38 mmol) and acetic anhydride (0.338 mL, 3.59 mmol) at 0 ° C. The mixture was heated to room temperature and stirred for 30 minutes. Distilled water was added to the reaction solution, and extracted with chloroform. The organic layer was washed with distilled water and saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, chloroform / methanol = 95/5), and (R) -1-acetyl-N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'- Biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 20) (1.02 g, 2.32 mmol, 64.6%) was obtained as a white solid. As a result of analysis using a chiral column, the retention time of the obtained compound of Example 20 was 32.8 minutes, and the optical purity at that time was 99.0% ee. The analysis conditions using a chiral column are as follows.
Measuring equipment; Shimadzu Corporation High-performance liquid chromatograph LC-2010CHT
Column; Daicel Chemical Industries, Ltd. CHIRALCEL OD-RH 0.46 cmφ × 15 cm particle diameter 5 μm
Column temperature: 40 ° C
Mobile phase: (Liquid A) 20 mM aqueous solution of potassium dihydrogen phosphate, (Liquid B) Composition of acetonitrile mobile phase; Liquid A: Liquid B = 60: 40 to 50:50 (0 to 40 minutes, linear gradient)
Solution A: Solution B = 50: 50 to 60: 40 (40 to 41 minutes, linear gradient)
Solution A: Solution B = 60: 40 (41 minutes to 50 minutes)
Flow rate: 0.5 mL / min detection; UV (210 nm)
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.63 (m, 1 H), 1.67 (d, J = 7.8 Hz, 1 H), 1.89 to 2.02 (m, 1) 2H), 2.22 (s, 3H), 2.29 (d, J = 12.9 Hz, 1 H), 3.22 (t, J = 13.2 Hz, 1 H), 3.78 (d, J = 12.7 Hz, 1 H), 5. 29 (d, J = 5.1 Hz, 1 H), 7. 20 (d, J = 8.3 Hz, 1 H), 7. 29-7. 37 (m, 3 H), 7.40-7.44 (m, 2H), 7.80 (br, 1 H), 8.65 (br, 1 H).
ESI-MS: m / z = 441 (M + H) ⁺ .

Example 21 (R) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (methylsulfonyl) piperidine-2-carboxamide Composition of:

(R) -N- (2-chloro-) by the same procedure as in Example 3 except for using the compound of Reference Example 8 in place of the compound of Reference Example 3 and methanesulfonyl chloride instead of propionyl chloride. 2 ′-(Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (methylsulfonyl) piperidine-2-carboxamide (hereinafter, the compound of Example 21) (0.0600 g, 0. 1 126 mmol, 99.0%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.47-1.61 (m, 1 H), 1.62-1.81 (m, 4 H), 2.45 (d, J = 10.4 Hz, 1H), 3.04 (s, 3 H), 3.23 (td, J = 13.3, 2.4 Hz, 1 H), 3.93 (t, J = 7.0 Hz, 1 H), 4.64 (4) br, 1 H), 7. 25 (d, J = 8.5 Hz, 1 H), 7.30-7. 38 (m, 3 H), 7.43 (dt, J = 10.8, 3.7 Hz, 2 H ), 7.84 (d, J = 2.2 Hz, 1 H), 8. 29 (br, 1 H).
ESI-MS: m / z = 477 (M + H) ⁺ .

(Example 22) (R) ^-N 2 - (2-chloro-2 '- (trifluoromethoxy) - [1,1'-biphenyl] -4-yl) piperidine-1,2-dicarboxamide:

To a solution of the compound of Reference Example 8 (3.00 g, 7.52 mmol) in dichloromethane (30 mL) was added trimethylsilyl isocyanate (2.00 mL, 15.04 mmol) and triethylamine (1.05 mL, 7.57 mmol) at 0 ° C. After heating to room temperature, the mixture was stirred for 18 hours. Methanol was added to the reaction solution and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, chloroform) to give, (R) ^-N 2 - (2-chloro-2 '- (trifluoromethoxy) - [1,1'-biphenyl] -4-yl) piperidine - 1,2-dicarboxamide (hereinafter, the compound of Example 22) (2.50 g, 5.66 mmol, 75.2%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.68 (m, 2H), 1.73 (br, 2H), 1.81-1.92 (m, 1H), 2.30 (D, J = 12.9 Hz, 1 H), 3.21 (dt, J = 12.8, 2.6 Hz, 1 H), 3.52 (d, J = 13.2 Hz, 1 H), 4.81 (d br, 2H), 5.03 (d, J = 4.6 Hz, 1 H), 7.20 (d, J = 8.3 Hz, 1 H), 7.29-7.37 (m, 3 H), 7. 42 (dt, J = 10.8, 3.8 Hz, 2 H), 7.81 (br, 1 H), 8.95 (br, 1 H).
ESI-MS: m / z = 442 (M + H) ⁺ .

Example 23 (R) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (2,2,2-trifluoro) Synthesis of Acetyl) piperidine-2-carboxamide:

Triethylamine (1.57 mL, 11.28 mmol) and trifluoroacetic anhydride (1.17 mL, 8.27 mmol) were added to a solution of the compound of Reference Example 8 (3.00 g, 7.52 mmol) in dichloromethane (75 mL) at 0 ° C. The mixture was stirred for 30 minutes after the temperature was raised to room temperature. Distilled water was added to the reaction solution, and extracted with chloroform. The organic layer was washed with distilled water and saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 20/80), (R) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl ] -4-yl) -1- (2,2,2-trifluoroacetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 23) (2.50 g, 5.05 mmol, 67.2%) with a white color Obtained as a solid. As a result of analysis using a chiral column, the retention time of the obtained compound of Example 23 was 33.6 minutes, and the optical purity at that time was 95.0% ee. The analysis conditions using a chiral column are as follows.
Measuring equipment; Shimadzu Corporation High-performance liquid chromatograph LC-2010CHT
Column; Daicel Chemical Industries, Ltd. CHIRALCEL OD-RH 0.46 cmφ × 15 cm particle diameter 5 μm
Column temperature: 40 ° C
Mobile phase: (Liquid A) 20 mM aqueous solution of potassium dihydrogen phosphate, (Liquid B) Composition of acetonitrile mobile phase; Liquid A: Liquid B = 60: 40 to 50:50 (0 to 40 minutes, linear gradient)
Solution A: Solution B = 50: 50 to 60: 40 (40 to 41 minutes, linear gradient)
Solution A: Solution B = 60: 40 (41 to 50 minutes)
Flow rate: 0.5 mL / min detection; UV (210 nm)
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.56-1.86 (m, 4 H), 1.98 (dt, J = 11.2, 4.6 Hz, 1 H), 2.36 (d, J = 14.1 Hz, 1 H), 3.37 (td, J = 13.4, 2.6 Hz, 1 H), 4.01 (d, J = 13.9 Hz, 1 H), 5.18 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.30 to 7.46 (m, 5 H), 7.79 (br, 1 H), 7.89 (br) , 1 H).
ESI-MS: m / z = 495 (M + H) ^<+> .

Reference Example 9 Synthesis of (1R, 5S) -2-((R) -1-phenylethyl) -6-oxa-2-azabicyclo [3.2.1] octan-7-one:

Potassium carbonate (4.09 g, 29.6 mmol) and 4-bromo-1-butene (3.01 mL) in a solution of (R) -α-methylbenzylamine (3.77 mL, 29.6 mmol) in DMF (30 mL) 29.6 mmol) was added at room temperature and stirred at the same temperature for 24 hours. Distilled water was added to the reaction solution and extracted with diethyl ether. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. Glyoxylic acid (4.09 mL, 36.8 mmol) was added to a solution of the residue in tetrahydrofuran (12 mL) at 0 ° C., and the mixture was heated to 60 ° C. and stirred for 9 hours. Distilled water and 1 M aqueous sodium hydroxide solution were added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, distilled water and saturated brine, then dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 9/9 to 85/15) to give (1R, 5S) -2-((R) -1-phenylethyl) -6-oxa- 2-azabicyclo [3.2.1] octan-7-one (hereinafter, the compound of Reference Example 9) (1.73 g, 7.48 mmol, 25.3%) was obtained as a pale yellow oil.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.33 (d, J = 6.6 Hz, 3 H), 1.82 (d, J = 11.7 Hz, 1 H), 1.87-1.95 ( m, 1H), 2.03-2.12 (m, 2H), 2.47 (td, J = 11.8, 5.1 Hz, 1H), 3.19 (d, J = 5.1 Hz, 1H) ), 3.35 (dd, J = 12.0, 6.6 Hz, 1 H), 3. 70 (q, J = 6.6 Hz, 1 H), 4.78 (t, J = 5.1 Hz, 1 H) , 7.23-7.27 (m, 1 H), 7.31-7. 35 (m, 2 H), 7. 39-7. 41 (m, 2 H).
ESI-MS: m / z = 232 (M + H) ⁺ .

Reference Example 10 Synthesis of (1R, 5S) -2- (tert-butoxycarbonyl) -6-oxa-2-azabicyclo [3.2.1] -octan-7-one:

In a solution of the compound of Reference Example 9 (1.73 g, 7.48 mmol) in ethyl acetate (25 mL), 20 wt% palladium hydroxide-carbon (50 wt% water content, 0.210 g) and di-tert-butyl dicarbonate 1.80 g (8.23 mmol) was added at room temperature and stirred at the same temperature for 36 hours under a hydrogen atmosphere. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure. The residue is suspended in diethyl ether / n-hexane = 1/9 (v / v), and the resulting solid is collected by filtration and then dried, and (1R, 5S) -2- (tert-butoxycarbonyl) -6-oxa -2-azabicyclo [3.2.1] -octan-7-one (hereinafter, the compound of Reference Example 10) (1.63 g, 7.17 mmol, 95.9%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48 (s, 9 H), 1.84-1. 93 (m, 1 H), 1.95 (d, J = 12.0 Hz, 1 H), 2 .03-2.06 (m, 1 H), 2.29-2.32 (m, 1 H), 3.18-2.21 (m, 1 H), 4.06 (m, 1 H), 4.70 -4.85 (m, 1 H), 4.97 (t, J = 5.1 Hz, 1 H).
ESI-MS: m / z = 228 (M + H) ⁺ .

Reference Example 11 (2R, 4S) -2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) -4-hydroxypiperidine-1 Synthesis of tert-butyl carboxylic acid:

To a solution of the compound of Reference Example 10 (0.320 g, 1.41 mmol) in toluene (2.3 mL) was added trimethylaluminum-toluene solution (1.4 M, 1.31 mL, 1.83 mmol) at 0 ° C. It stirred for 30 minutes after temperature rising. A solution of the compound of Reference Example 1 (0.486 g, 1.690 mmol) in toluene (2.3 mL) was added, and the mixture was heated to 50 ° C. and stirred for 4 hours. To the reaction mixture was added 1 M hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic layer was washed with distilled water and saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 80/20 to 50/50) to give (2R, 4S) -2-((2-chloro-2 '-(trifluoromethoxy)- [1,1′-Biphenyl] -4-yl) carbamoyl) -4-hydroxypiperidine-1-carboxylic acid tert-butyl (hereinafter compound of Reference Example 11) (0.654 g, 1.27 mmol, 90.2% ) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.54 (s, 9 H), 1.66-1.69 (m, 1 H), 1.78-1.82 (m, 1 H), 1.93 -2.00 (m, 1 H), 2.40 (d, J = 13.4 Hz, 1 H), 3. 25 (td, J = 13.2, 2.4 Hz, 1 H), 3.86-3. 88 (m, 1 H), 4.12-4.14 (m, 1 H), 4.98-5.00 (m, 1 H), 5. 20 (br, 1 H), 7.24 (d, J = 8.3 Hz, 1 H), 7.30-7.46 (m, 5 H), 7.75-7. 78 (m, 1 H), 9.08 (br, 1 H).
ESI-MS: m / z = 515 (M + H) ^<+> .

Reference Example 12 (2R, 4S) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4-hydroxypiperidine-2-carboxamide Hydrochloride Salt synthesis:

Hydrogen chloride-ethyl acetate solution (4.0 M, 0.486 mL, 1.94 mmol) was added to a solution of the compound of Reference Example 11 (0.0500 g, 0.0973 mmol) in ethyl acetate (0.5 mL) at 0 ° C. The mixture was heated to room temperature and stirred for 3 hours. The reaction solution is filtered and the solid collected by filtration is washed with ethyl acetate and then dried, and (2R, 4S) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl]- 4-yl) -4-hydroxypiperidine-2-carboxamide hydrochloride (hereinafter, the compound of Reference Example 12) (0.0409 g, 0.0908 mmol, 93.3%) was obtained as a white solid.
¹ H-NMR (DMSO-D ₆ ) δ: 1.46 to 1.62 (m, 2H), 1.91-1.94 (m, 1H), 2.42-2.45 (m, 1H) , 3.01 (t, J = 12.2 Hz, 1 H), 3.28-3. 32 (m, 1 H), 3.69-3. 78 (m, 1 H), 4.00 (d, J = 12.0 Hz, 1 H), 5. 28 (d, J = 4.9 Hz, 1 H), 7. 38 (d, J = 8.3 Hz, 1 H), 7.42 (dd, J = 7.8, 1 .7 Hz, 1 H), 7.48-7.52 (m, 2 H), 7.5 6-7.64 (m, 2 H), 7.94 (s, 1 H), 8.93 (br, 1 H), 11.00 (s, 1 H).
ESI-MS: m / z = 415 (M + H) ⁺ .

(Reference Example 13) (2R, 4R) -2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) -4-fluoropiperidine-1 Synthesis of tert-butyl carboxylic acid:

(Diethylamino) sulfur trifluoride (0.0380 mL, 0.291 mmol) was added to a solution of the compound of Reference Example 11 (0. 100 g, 0.194 mmol) in dichloromethane (1.9 mL) at -78.degree. C., and the temperature was raised to room temperature. It stirred after 24 hours. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 90/10 to 80/20) to give (2R, 4R) -2-((2-chloro-2 '-(trifluoromethoxy)- [1,1′-Biphenyl] -4-yl) carbamoyl) -4-fluoropiperidine-1-carboxylic acid tert-butyl (hereinafter compound of Reference Example 13) (0.0272 g, 0.0527 mmol, 27.2% ) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48 to 1.56 (m, 1 H), 1.54 (s, 9 H), 1.59 to 1. 86 (m, 2 H), 2.07 -2.19 (m, 1 H), 2.65-2.71 (m, 1 H), 2.93 (t, J = 12.8 Hz, 1 H), 4.14-4.13 (m, 1 H) , 5.04-5.06 (m, 1 H), 7.22 (d, J = 8.3 Hz, 1 H), 7.29-7.36 (m, 4 H), 7.41-7. 45 ( m, 1 H), 7.76 (br, 1 H).
ESI-MS: m / z = 517 (M + H) ⁺ .

(Reference Example 14) (2R, 4R) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4-fluoropiperidine-2-carboxamide hydrochloride Salt synthesis:

(2R, 4R) -N- (2-chloro-2 '-(trifluoromethoxy) By using the compound of Reference Example 13 in place of the compound of Reference Example 11 and using the same procedure as in Reference Example 12 except the above. -[1,1'-biphenyl] -4-yl) -4-fluoropiperidine-2-carboxamide hydrochloride (hereinafter referred to as the compound of Reference Example 14) (0.0186 g, 0.0410 mmol, 84.9%) to a white color Obtained as a solid.
¹ H-NMR (DMSO-D ₆ ) δ: 1.89-2.06 (m, 2H), 2.24-2.33 (m, 1H), 3.12-3.27 (m, 2H) , 4.18 (d, J = 12.4 Hz, 1 H), 5.16 (d, J = 47.1 Hz, 1 H), 7.38 (d, J = 8.5 Hz, 1 H), 7.42 (d dd, J = 7.9, 1.8 Hz, 1 H), 7.48-7.52 (m, 2 H), 7.56-7.61 (m, 2 H), 7.95 (br, 1 H), 9.12 (br, 1 H), 10. 97 (s, 1 H).
ESI-MS: m / z = 417 (M + H) ⁺ .

(Reference Example 15) (2R, 4R) -2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) -4- (formyloxy) Synthesis of tert-butyl piperidine-1-carboxylic acid:

To a solution of triphenylphosphine (0.153 g, 0.583 mmol) in tetrahydrofuran (1.0 mL) was added diisopropyl azodicarboxylate (0.113 mL, 0.583 mmol) at 0 ° C., and after stirring for 1 hour at the same temperature, formic acid (0.0220 mL, 0.583 mmol) was added and stirred at the same temperature for 30 minutes. A solution of the compound of Reference Example 11 (0.200 g, 0.388 mmol) in tetrahydrofuran (1.00 mL) was added dropwise, and the mixture was warmed to room temperature and stirred for 12 hours. The reaction solution is concentrated under reduced pressure, and the residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 85 / 15-70 / 30) to obtain (2R, 4R) -2-((2-chloro-2 ′) -(Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) -4- (formyloxy) piperidine-1-carboxylic acid tert-butyl (following, compound of Reference Example 15) (0. 1). 0939 g (0.173 mmol, 44.5%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.28-1.37 (m, 2 H), 1.54 (s, 9 H), 1.67-1. 74 (m, 1 H), 2.07 −2.12 (m, 1 H), 2.61-2.63 (m, 1 H), 2.96-3. 02 (m, 1 H), 4.12−4. 14 (m, 1 H), 5 .06 (br, 1 H), 5.43 (br, 1 H), 7.22 (d, J = 8.3 Hz, 1 H), 7.32-7.37 (m, 3 H), 7.41-7 45 (m, 2H), 7.80 (br, 1 H), 8.06 (s, 1 H).
ESI-MS: m / z = 543 (M + H) ⁺ .

(Reference Example 16) (2R, 4R) -2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) -4-hydroxypiperidine-1 Synthesis of tert-butyl carboxylic acid:

To a solution of the compound of Reference Example 15 (0.0900 g, 0.166 mmol) in methanol (1.1 mL) was added sodium methoxide-methanol solution (4.0 M, 0.0207 mL, 0.0828 mmol) at 0 ° C. Stir at temperature for 15 minutes. To the reaction mixture was added 1 M hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 80/20 to 50/50) to give (2R, 4R) -2-((2-chloro-2 ′-(trifluoromethoxy)- [1,1′-Biphenyl] -4-yl) carbamoyl) -4-hydroxypiperidine-1-carboxylic acid tert-butyl (hereinafter compound of Reference Example 16) (0.0844 g, 0.164 mmol, 99.3% ) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.54 (m, 2 H), 1.54 (s, 9 H), 1.68 to 1.71 (m, 1 H), 1.94 -1.97 (m, 1 H), 2.54-2. 56 (m, 1 H), 2.86-2.93 (m, 1 H), 4.13-4.22 (m, 2 H), 5 .04 (br, 1 H), 7.22 (d, J = 8.3 Hz, 1 H), 7.30-7.45 (m, 5 H), 7.78 (br, 1 H), 8.52 (s , 1 H).
ESI-MS: m / z = 515 (M + H) ^<+> .

(Reference Example 17) (R) -2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) -4-oxopiperidine-1-carvone Synthesis of acid tert-butyl:

Dess-Martin periodinane (0.190 g, 0.449 mmol) is added to a solution of the compound of Reference Example 11 (0.210 g, 0.408 mmol) in dichloromethane (2.0 mL) at 0 ° C., and the temperature is raised to room temperature. Stir for 3 hours. To the reaction mixture was added aqueous sodium thiosulfate solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with distilled water and saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 90/10 to 60/40) to give (R) -2-((2-chloro-2 '-(trifluoromethoxy)-[1 , 1′-biphenyl] -4-yl) carbamoyl) -4-oxopiperidine-1-carboxylic acid tert-butyl (hereinafter compound of Reference Example 17) (0.190 g, 0.370 mmol, 90.9%) Obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.56 (s, 9 H), 2.46-2.53 (m, 1 H), 2.61-2. 73 (m, 2 H), 3.00 (Dd, J = 16.5, 3.3 Hz, 1 H), 3.66-3. 73 (m, 1 H), 3.82 (br, 1 H), 5.05 (s, 1 H), 7.22 (D, J = 8.3 Hz, 1 H), 7.29-7.36 (m, 3 H), 7.41-7. 45 (m, 2 H), 7.78 (br, 1 H), 9.14 (Br, 1H).
ESI-MS: m / z = 513 (M + H) ^<+> .

(Reference Example 18) (R) -2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) -4,4-difluoropiperidine-1 Synthesis of tert-butyl carboxylic acid:

(Diethylamino) sulfur trifluoride (0.108 mL, 0.815 mmol) is added at 0 ° C. to a solution of the compound of Reference Example 17 (0.190 g, 0.370 mmol) in dichloromethane (1.9 mL), and the temperature is raised to room temperature. Stir for 24 hours. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 85/15 to 70/30) to give (R) -2-((2-chloro-2 ′-(trifluoromethoxy)-[1 , 1′-Biphenyl] -4-yl) carbamoyl) -4,4-difluoropiperidine-1-carboxylic acid tert-butyl (hereinafter compound of Reference Example 18) (0.0393 g, 0.0735 mmol, 19.8% ) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.54 (s, 9 H), 1.86-2.15 (m, 3 H), 2.99-3.07 (m, 1 H), 3.21 (Td, J = 13.3, 2.7 Hz, 1 H), 4.22-4. 25 (m, 1 H), 5.07 (br, 1 H), 7.24 (d, J = 8.5 Hz, 1H), 7.30-7.37 (m, 3H), 7.41-7.46 (m, 2H), 7.76 (s, 1H), 7.97 (br, 1H).
ESI-MS: m / z = 535 (M + H) ⁺ .

Example 24 (2R, 4S) -1-Acetyl-N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4-hydroxypiperidine- Synthesis of 2-carboxamide:

(2R, 4S) -1-Acetyl-N--A by the procedure of Example 3 except for using the compound of Reference Example 12 in place of the compound of Reference Example 3 and acetyl chloride instead of propionyl chloride (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -4-hydroxypiperidine-2-carboxamide (hereinafter, the compound of Example 24) (0.0166 g, 0.0363 mmol, 91.1%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.68-1.76 (m, 1 H), 1.87-1.98 (m, 2 H), 2.24 (s, 3 H), 2.39 (D, J = 14.6 Hz, 1 H), 3.50-3.57 (m, 1 H), 3.61-3.66 (m, 1 H), 4.14-4. 17 (m, 1 H) , 5.42 (d, J = 6.8 Hz, 1 H), 5.52 (d, J = 6.8 Hz, 1 H), 7.23 (d, J = 8.5 Hz, 1 H), 7.31- 7.37 (m, 3 H), 7.41-7. 46 (m, 2 H), 7.77 (br, 1 H), 9. 15 (s, 1 H).
ESI-MS: m / z = 457 (M + H) ^<+> .

Example 25 (2R, 4R) -1-Acetyl-N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4-fluoropiperidine- Synthesis of 2-carboxamide:

(2R, 4R) -1-Acetyl-N--A by the same procedure as in Example 3 except for using the compound of Reference Example 14 in place of the compound of Reference Example 3 and acetyl chloride instead of propionyl chloride (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4-fluoropiperidine-2-carboxamide (compound of Example 25 below) (0.0108 g, 0.0235 mmol, 62.8%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.69-1 to 85 (m, 2 H), 2.22-2 to 25 (m, 1 H), 2.25 (s, 3 H), 2.62 -2.69 (m, 1 H), 3.21-3.28 (m, 1 H), 3.85 (dd, J = 13.4, 2.9 Hz, 1 H), 5.24-5. 43 ( m, 1 H), 5.43 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.30-7.36 (m, 3 H), 7. 41-7.45 (m, 2 H), 7. 70-7.8 2 (m, 1 H), 8. 72 (s, 1 H).
ESI-MS: m / z = 459 (M + H) ^<+> .

Example 26 (2R, 4S) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4-hydroxy-1- (methylsulfonyl) ) Synthesis of piperidine-2-carboxamide:

(2R, 4S) -N- (2-) in the same manner as in Example 3 except that the compound of Reference Example 12 is used instead of the compound of Reference Example 3, and methanesulfonyl chloride is used instead of propionyl chloride. Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -4-hydroxy-1- (methylsulfonyl) piperidine-2-carboxamide (a compound of Example 26 below) 0.00841 g (0.0171 mmol, 42.7%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.68-1.76 (m, 1 H), 1.85-1. 88 (m, 1 H), 1.99 (ddd, J = 14.9, 6.9, 3.1 Hz, 1 H), 2.61 (d, J = 14.9 Hz, 1 H), 3.03 (s, 3 H), 3.55-3. 62 (m, 1 H), 72 (d, J = 4.6 Hz, 1 H), 3.75-3. 79 (m, 1 H), 4.22-4.24 (m, 1 H), 4.66 (d, J = 6.6 Hz) , 1H), 7.25-7.27 (m, 1H), 7.31-7.37 (m, 3H), 7.42-7.46 (m, 2H), 7.81 (d, J) = 2.0 Hz, 1 H), 8. 58 (s, 1 H).
ESI-MS: m / z = 493 (M + H) ⁺ .

Example 27 (2R, 4R) -1-Acetyl-N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4-hydroxypiperidine- Synthesis of 2-carboxamide:

Hydrogen chloride-ethyl acetate solution (4.0 M, 0.194 mL, 1.94 mmol) was added to a solution of the compound of Reference Example 16 (0.0200 g, 0.0388 mmol) in ethyl acetate (0.4 mL) at 0 ° C. The mixture was heated to room temperature and stirred for 3 hours. The reaction solution is concentrated under reduced pressure, and the residue is dissolved in dichloromethane (0.8 mL), and then triethylamine (0.00135 mL, 0.0970 mmol) and acetyl chloride (0.00359 mL, 0.0504 mmol) are added at 0 ° C., and the same temperature is added. The mixture was stirred for 1 hour. Methanol was added to the reaction solution and concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, ethyl acetate / methanol = 100/0 to 97/3), and (2R, 4R) -1-acetyl-N- (2-chloro-2 '-(trifluoromethoxy) -[1,1'-biphenyl] -4-yl) -4-hydroxypiperidine-2-carboxamide (hereinafter, the compound of Example 27) (0.0106 g, 0.0232 mmol, 59.7%) as a white solid Obtained.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.47-1.57 (m, 2 H), 1.81 (d, J = 3.6 Hz, 1 H), 2.04-2.09 (m, 1H), 2.25 (s, 3 H), 2.50 (ddt, J = 13.1, 5.0, 1.8 Hz, 1 H), 3.22 (td, J = 13.4, 2.6 Hz , 1H), 3.85 (d, J = 13.4 Hz, 1 H), 4.40-4.48 (m, 1 H), 5.43 (d, J = 5.9 Hz, 1 H), 7.21 (D, J = 8.2 Hz, 1 H), 7.30-7.37 (m, 3 H), 7.41-7. 45 (m, 2 H), 7.69-7. 83 (m, 1 H) , 8.65 (s, 1 H).
ESI-MS: m / z = 457 (M + H) ^<+> .

Example 28 (R) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -4,4-difluoro-1- (methylsulfonyl) ) Synthesis of piperidine-2-carboxamide:

(R) -N- (2-chloro-) according to the procedure of Example 27 except using the compound of Reference Example 18 in place of the compound of Reference Example 16, and using methanesulfonyl chloride instead of acetyl chloride. 2 ′-(Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -4,4-difluoro-1- (methylsulfonyl) piperidine-2-carboxamide (the compound of Example 28 below) 0.0127 g (0.0248 mmol, 77.0%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.95-2.12 (m, 1 H), 2.15-2.32 (m, 2 H), 2.95-3. 02 (m, 1 H) , 3.10 (s, 3 H), 3. 60 (td, J = 13.5, 3.0 Hz, 1 H), 4.02-4.08 (m, 1 H), 4.89 (d, J = 7.2 Hz, 1 H), 7.26 (d, J = 8.2 Hz, 1 H), 7.30 to 7.37 (m, 3 H), 7.42 to 7.46 (m, 2 H), 7. 76 (s, 1 H), 7.93 (s, 1 H).
ESI-MS: m / z = 513 (M + H) ^<+> .

Reference Example 19 Synthesis of tert-butyl 2- (N-methylmethylsulfonamido) acetate:

2- (Methylamino) acetic acid tert-butyl hydrochloride (0.100 g, 0.550 mmol) in dichloromethane (2.0 mL) solution, triethylamine (0.192 mL, 1.385 mmol) and methanesulfonyl chloride (0.0515 mL, 0.661 mmol) was added at 0 ° C., and the mixture was warmed to room temperature and stirred for 3 hours. To the reaction mixture was added saturated aqueous ammonium chloride solution, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, n-hexane / ethyl acetate = 90/10 to 70/30), tert-butyl 2- (N-methylmethylsulfonamido) acetate (following, compound of Reference Example 19) (0.117 g, 0.524 mmol, 95.2%) was obtained as a colorless oil.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48 (s, 9 H), 2.98 (s, 3 H), 3.00 (s, 3 H), 3.98 (s, 2 H).

Reference Example 20 Synthesis of 2- (N-methylmethylsulfonamido) acetic acid:

Hydrogen chloride-ethyl acetate solution (4.0 M, 1.31 mL, 5.24 mmol) is added to a solution of the compound of Reference Example 19 (0.117 g, 0.524 mmol) in acetonitrile (1.5 mL) at 0 ° C. The mixture was stirred for 16 hours after the temperature rise. The reaction mixture was concentrated under reduced pressure to give crude 2- (N-methylmethylsulfonamido) acetic acid (hereinafter, the compound of Reference Example 20) (0.0855 g) as a colorless oil. The compound of Reference Example 20 was used as it was in the next reaction.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 2.99 (s, 3 H), 3.01 (s, 3 H), 4. 14 (s, 2 H).
ESI-MS: m / z = 168 (M + H) ⁺ .

Example 29 (R) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfone) Synthesis of Amid) acetyl) piperidine-2-carboxamide:

A solution of the compound of Reference Example 8 (0.184 g, 0.462 mmol) in DMF (1.0 mL) in a solution of the compound of Reference Example 20 (0.0850 g, 0.508 mmol) in DMF (2.0 mL), HATU (0 193 g (0.508 mmol) and diisopropylethylamine (0.121 mL, 0.693 mmol) were added at room temperature and stirred at the same temperature for 18 hours. Distilled water was added to the reaction mixture, and the mixture was extracted with a mixed solvent of n-hexane / ethyl acetate = 20/80 (v / v). The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 50/50 to 30/70) and (R) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1 1′-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 29) (0.209 g, 0.380 mmol, 82) .0%) was obtained as a white solid. As a result of analysis using a chiral column, the retention time of the obtained compound of Example 29 was 34.5 minutes, and the optical purity at that time was 98.2% ee. The analysis conditions using a chiral column are as follows.
Measuring equipment; Shimadzu Corporation High-performance liquid chromatograph LC-2010CHT
Column; Daicel Chemical Industries, Ltd. CHIRALCEL OD-RH 0.46 cmφ × 15 cm particle diameter 5 μm
Column temperature: 40 ° C
Mobile phase: (Liquid A) 20 mM aqueous solution of potassium dihydrogen phosphate, (Liquid B) Composition of acetonitrile mobile phase; Liquid A: Liquid B = 60: 40 to 50:50 (0 to 40 minutes, linear gradient)
Solution A: Solution B = 50: 50 to 60: 40 (40 to 41 minutes, linear gradient)
Solution A: Solution B = 60: 40 (41 to 50 minutes)
Flow rate: 0.5 mL / min detection; UV (210 nm)
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.52-1.89 (m, 5 H), 2.35-2.38 (m, 1 H), 3.03-3. 07 (m, 6 H) , 3.20-3.31 (m, 1 H), 3.67-3. 76 (m, 1 H), 4.16-4. 27 (m, 2 H), 5.25-5. 26 (m, 1H), 7.21-7.23 (m, 1H), 7.30-7.45 (m, 5H), 7.83 (s, 1H), 8.22 (br, 1H).
ESI-MS: m / z = 548 (M + H) ^<+> .

(Reference Example 21) (3- (2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -3- Synthesis of tert-butyl oxopropyl) carbamate:

By using 3-((tert-butoxycarbonyl) amino) propanoic acid instead of 2-methoxyacetic acid, and using the same procedure as in Example 4 except that (3- (2-((2-chloro-2 ′) -(Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -3-oxopropyl) carbamic acid tert-butyl (the compound of Reference Example 21 below) (0 .288 g, 0.505 mmol, quantitative) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.39 (s, 9 H), 1.50-1. 90 (5 H, m), 2. 35 (d, J = 13.7 Hz, 1 H), 2 .55-2.75 (m, 2 H), 3.20 (t, J = 12.8 Hz, 1 H), 3.41-3.49 (m, 1 H), 3.50-3.60 (m, 2) 1H), 3.80 (d, J = 13.7 Hz, 1H) 5.17 (br, 1H), 5.33 (d, J = 4.9 Hz, 1H), 7.20 (d, J = 8) 3 Hz, 1 H), 7. 29-7. 60 (m, 5 H), 7. 7-7. 89 (m, 1 H), 8. 65 (br, 1 H).
ESI-MS: m / z = 570 (M + H) ⁺ .

Example 30 1- (3-Aminopropanoyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide Synthesis:

Using the compound of Reference Example 21 instead of the compound of Reference Example 4 and using the same procedure as Reference Example 5 except the above, 1- (3-aminopropanoyl) -N- (2-chloro-2 '-( Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 30) (0.155 g, 0.329 mmol, 65.6%) as a white solid Obtained.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.82 (m, 5 H), 2.43 (d, J = 13.1 Hz, 1 H) 2.56 (dt, J = 15.3) , 6.2 Hz, 1 H), 2.71-2. 79 (m, 1 H), 3.0 9-32. 21 (m, 3 H), 3. 88 (d, J = 13.1 Hz, 1 H), 5 .43 (d, J = 5.0 Hz, 1 H), 7.19 (d, J = 8.2 Hz, 1 H), 7.29-7.36 (m, 3 H), 7.47-7.85 ( m, 3H), 8.96 (br, 1H).
ESI-MS: m / z = 470 (M + H) ⁺ .

Example 31 1- (3-acetamidopropanoyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide Synthesis:

The procedure of Example 3 is repeated except that the compound of Example 30 is used instead of the compound of Reference Example 3 and acetyl chloride is used instead of propionyl chloride, and 1- (3-acetamidopropanoyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 31) (0.0218 g, 0.0420 mmol, 99.1%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.94 (m, 5 H), 1.98 (s, 3 H), 2.34 (d, J = 13.3 Hz, 1 H), 2 .60-2.73 (m, 2H), 3.20 (td, J = 13.3, 2.4 Hz, 1H), 3.52-3.70 (m, 2H), 3.79 (d, J = 13.3 Hz, 1 H), 5.30 (d, J = 4.5 Hz, 1 H), 6.23 (br, 1 H), 7.21 (d, J = 8.2 Hz, 1 H), 7. 30-7.90 (m, 6H), 8.51 (br, 1H).
ESI-MS: m / z = 512 (M + H) ⁺ .

Example 32 N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (3- (methylsulfonamido) propanoyl) piperidine-2 -Synthesis of carboxamide:

N- (2-chloro-2 ′-(N- (2-chloro-2 ′-()) by a procedure similar to that of Example 3 except that the compound of Example 30 is used instead of the compound of Reference Example 3, and methanesulfonyl chloride is used instead of propionyl chloride. Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (3- (methylsulfonamido) propanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 32) (0.0224 g, 0.0409 mmol, 96.1%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.90 (m, 5 H), 2.33 (d, J = 13.5 Hz, 1 H), 2.75-2.80 (m, 5) 2H) 3.00 (s, 3 H), 3.22 (t, J = 13.5 Hz, 1 H), 3.45-3.51 (m, 2 H), 3.77 (d, J = 13.5 Hz) , 1H), 5.26-5.30 (m, 2H), 7.22 (d, J = 8.3 Hz, 1H), 7.30-7.44 (m, 5H), 7.80 (br) , 1 H), 8.22 (br, 1 H).
ESI-MS: m / z = 548 (M + H) ^<+> .

Example 33 N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (3- (dimethylamino) propanoyl) piperidine-2- Carboxamide Synthesis:

N- (2-Chloro-2 '-(trifluoromethoxy)-[N-], following the procedure as in Example 4 but using 3- (dimethylamino) propanoic acid hydrochloride instead of 2-methoxyacetic acid 1,1′-biphenyl] -4-yl) -1- (3- (dimethylamino) propanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 33) (0.0274 g, 0.0550 mmol, 73.2) %) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.49-1.83 (m, 5 H), 2.27 (s, 6 H), 2.38-2.45 (m, 1 H), 2.56 -2.61 (m, 1 H), 2.66-2.80 (m, 3 H), 3.12-3. 20 (m, 1 H), 3.85-3. 93 (m, 1 H), 5 .42 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7. 27-7. 45 (m, 6 H), 8. 73 (br, 1 H) .
ESI-MS: m / z = 498 (M + H) ⁺ .

Reference Example 22 (3- (2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -3- Synthesis of tert-butyl oxopropyl) (methyl) carbamate:

A procedure similar to that of Example 4 was carried out using 3-((tert-butoxycarbonyl) (methyl) amino) propanoic acid instead of 2-methoxyacetic acid, and using the same procedure as in Example 4, -2 '-(Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -3-oxopropyl) (methyl) carbamic acid tert-butyl (hereinafter referred to as a reference example) 22 compounds (0.130 g, 0.223 mmol, 89.0%) were obtained as white solids.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.35 (s, 9 H), 1.30-1.77 (m5 H), 2.37-2.80 (m, 3 H), 2.93 ( s, 3 H), 3.18-3. 30 (m, 2 H) 3. 84 (d, J = 13.7 Hz, 1 H), 3.95-4. 03 (m, 1 H), 5. 38-5 .42 (m, 1 H), 7.20 (d, J = 8.3 Hz, 1 H), 7.31-7. 46 (m, 4 H), 7.66-7.72 (m, 1 H), 7 90-7.92 (m, 1 H), 9. 10 (br, 1 H).
ESI-MS: m / z = 584 (M + H) ⁺ .

Example 34 N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (3- (methylamino) propanoyl) piperidine-2- Carboxamide Synthesis:

N- (2-chloro-2 '-(trifluoromethoxy)-[1,1' was prepared according to the same procedure as in Reference Example 5 except for using the compound of Reference Example 22 instead of the compound of Reference Example 4. -Biphenyl] -4-yl) -1- (3- (methylamino) propanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 34) (0.804 g, 0.166 mmol, 74.6%) as white Obtained as a solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.83 (m, 5 H), 2.47 (s, 3 H), 2.40 to 2.48 (m, 1 H), 2.75 −2.83 (m, 1H), 2.94−2.99 (m, 2H), 3.16 (td, J = 13.1, 2.6 Hz, 1H), 3.88 (d, J = 13.1 Hz, 1 H), 5.41 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.30-7.81 (m, 6 H), 8.80 (br, 1 H).
ESI-MS: m / z = 484 (M + H) ⁺ .

Example 35 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3- (N-methylacetamido) propanoyl) piperidine Synthesis of 2-carboxamide:

N- (2-chloro-2 '-(tri) by the same procedure as in Example 3 except for using the compound of Example 34 in place of the compound of Reference Example 3 and acetyl chloride instead of propionyl chloride Fluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3- (N-methylacetamido) propanoyl) piperidine-2-carboxamide (hereinafter compound of Example 35) (0.0316 g, 0.0601 mmol, 74.5%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48-1.77 (m, 5 H), 2.09 (s, 3 H), 2.45 (d, J = 13.7 Hz, 1 H), 2 .59-2.79 (m, 2H), 3.11 (s, 3H), 3.20-3.29 (m, 2H), 3.84 (d, J = 13.7 Hz, 1H), 4 21-4.28 (m, 1H), 5.35 (d, J = 5.1 Hz, 1 H), 7.20 (d, J = 8.3 Hz, 1 H), 7.31-7. 36 ( m, 3H), 7.38-7.44 (m, 1 H), 7. 7-7. 80 (m, 1 H), 7.97-8. 0 6 (m, 1 H), 9. 9 (br, 1H).
ESI-MS: m / z = 526 (M + H) ⁺ .

Example 36 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3- (N-methylmethylsulfonamido) propanoyl) Synthesis of piperidine-2-carboxamide:

N- (2-chloro-2 ′-(N- (2-chloro-2 ′-()) by a procedure similar to that of Example 3 except that the compound of Example 34 is used instead of the compound of Reference Example 3, and methanesulfonyl chloride is used instead of propionyl chloride. Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3- (N-methylmethylsulfonamido) propanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 36) (0 .380 g (0.0676 mmol, 86.2%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.98 (m, 5 H), 2.35 (d, J = 13.5 Hz, 1 H), 2.76 (dt, J = 15. 9, 7.0 Hz, 1H) 2.86 (s, 3 H), 2.83-2 2.89 (m, 1 H), 2.95 (s, 3 H), 3. 20 (td, J = 13.5) , 2.7 Hz, 1 H), 3.50-3.57 (m, 2 H), 3. 85 (d, J = 13.5 Hz, 1 H), 5.31 (d, J = 5.0 Hz, 1 H) , 7.21 (d, J = 8.2 Hz, 1 H), 7.30-7.36 (m, 3 H), 7.40-7.52 (m, 2 H), 7.80-7.83 ( m, 1 H), 8.42 (br, 1 H).
ESI-MS: m / z = 584 (M + H) ⁺ .

Reference Example 23 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (ethylamino) acetyl) piperidine-2- Carboxamide Synthesis:

A solution of the compound of Reference Example 5 (0.0400 g, 0.0877 mmol) in dichloromethane (1.0 mL), a solution of acetaldehyde (0.00464 g, 0.105 mmol) in dichloromethane (0.0600 mL), acetic acid (0.00050 mL, 0) .00877 mmol) and sodium triacetoxyborohydride (0.0279 mg, 0.132 mmol) were added at 0 ° C., and the mixture was warmed to room temperature and stirred for 2.5 hours. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (amine silica gel, n-hexane / ethyl acetate = 40/60 to 0/100) to give N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'- Biphenyl] -4-yl) -1- (2- (ethylamino) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Reference Example 23) (0.0193 g, 0.00399 mmol, 45.5%) as a white solid Got as.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.17 (t, J = 7.1 Hz, 3 H), 1.38-1.80 (m, 5 H), 1.90-2.00 (m, 1H), 2.30-2.45 (m, 1H), 2.55-2.90 (m, 2H), 3.16 (t, J = 13.3 Hz, 1H), 3.56 (s, 2H), 3.70-3.76 (m, 1H), 5.29 (d, J = 4.9 Hz, 1H), 7.20-7.45 (m, 6H), 7.70-7. 90 (m, 1 H), 8. 46 (s, 1 H).
ESI-MS: m / z = 484 (M + H) ⁺ .

Example 37 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (N-ethylmethylsulfonamido) acetyl) Synthesis of piperidine-2-carboxamide:

N- (2-chloro-2 ′-(N- (2-chloro-2 ′-()) by a procedure similar to Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (N-ethylmethylsulfonamido) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 37) (0 0.015 g (0.0311 mmol, 78.1%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.25 (t, J = 7.1 Hz, 3 H), 1.50-1.90 (m, 5 H), 2.38 (d, J = 13. 0 Hz, 1 H), 3.07 (s, 3 H), 3. 25 (t, J = 13.0 Hz, 1 H), 3.43 (q, J = 7.1 Hz, 2 H), 3.76 (d, J = 13.0 Hz, 1 H), 4.14 (d, J = 17.0 Hz, 1 H), 4.30 (d, J = 17.0 Hz, 1 H), 5.27 (d, J = 4.6 Hz , 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.29-7.36 (m, 3H), 7.40-7.45 (m, 2H), 7.83-7 .85 (m, 1 H), 8.23 (br, 1 H).
ESI-MS: m / z = 584 (M + Na) ⁺ .

(Reference Example 24) (R)-(3- (2- (2-((2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl Synthesis of tert-butyl) -3-oxopropyl) carbamate:

Using the same procedure as in Example 4 except using 3-((tert-butoxycarbonyl) amino) propanoic acid instead of 2-methoxyacetic acid, and using the compound of Reference Example 8 instead of the compound of Reference Example 3 , (R)-(3- (2- (2-((2-chloro-2 '-(trifluoromethoxy)-[1, 1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -3- Tert-butyl oxopropyl) carbamate (hereinafter, the compound of Reference Example 24) (0.104 g, 0.182 mmol, 96.7%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.39 (s, 9 H), 1.50-1. 90 (5 H, m), 2. 35 (d, J = 13.7 Hz, 1 H), 2 .55-2.75 (m, 2 H), 3.20 (t, J = 12.8 Hz, 1 H), 3.41-3.49 (m, 1 H), 3.50-3.60 (m, 2) 1H), 3.80 (d, J = 13.7 Hz, 1H) 5.17 (br, 1H), 5.33 (d, J = 4.9 Hz, 1H), 7.20 (d, J = 8) 3 Hz, 1 H), 7. 29-7. 60 (m, 5 H), 7. 7-7. 89 (m, 1 H), 8. 65 (br, 1 H).
ESI-MS: m / z = 570 (M + H) ⁺ .

Example 38 (R) -1- (3-aminopropanoyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine- Synthesis of 2-carboxamide:

(R) -1- (3-aminopropanoyl) -N- (2-chloro-) by using the compound of Reference Example 24 instead of the compound of Reference Example 4 and using the same procedure as in Reference Example 5 except the above. 2 ′-(Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter compound of Example 38) (0.497 g, 0.106 mmol, 58.5%) Was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.82 (m, 5 H), 2.43 (d, J = 13.1 Hz, 1 H) 2.56 (dt, J = 15.3) , 6.2 Hz, 1 H), 2.71-2. 79 (m, 1 H), 3.0 9-32. 21 (m, 3 H), 3. 88 (d, J = 13.1 Hz, 1 H), 5 .43 (d, J = 5.0 Hz, 1 H), 7.19 (d, J = 8.2 Hz, 1 H), 7.29-7.36 (m, 3 H), 7.47-7.85 ( m, 3H), 8.96 (br, 1H).
ESI-MS: m / z = 470 (M + H) ⁺ .

Example 39 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3- (methylthio) propanoyl) piperidine-2-carboxamide Composition of:

The procedure is as in Example 4 except that 3- (methylthio) propanoic acid is used instead of 2-methoxyacetic acid, and N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1 is obtained by the same procedure as Example 4. '-Biphenyl] -4-yl) -1- (3- (methylthio) propanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 39) (0.0489 g, 0.0976 mmol, 97.4%) was white colored Obtained as a solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.51-1.90 (m, 5 H), 2.18 (s, 3 H), 2.36 (d, J = 13.9 Hz, 1 H), 2 .68-2.77 (m, 1 H), 2.80- 2.99 (m, 3 H), 3.17 (td, J = 13.2, 2.6 Hz, 1 H), 3.86 (d, J = 12.4 Hz, 1 H), 5.37 (d, J = 4.9 Hz, 1 H), 7.20 (d, J = 8.3 Hz, 1 H), 7.30-7.52 (m, 5 H) ), 7.66-7.90 (m, 1 H), 8. 49 (br, 1 H).
ESI-MS: m / z = 501 (M + H) ⁺ .

Example 40 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3- (methylsulfonyl) propanoyl) piperidine-2- Carboxamide Synthesis:

To a solution of the compound of Example 39 (0.0480 g, 0.0958 mmol) in dichloromethane (1.0 mL) was added 3-chloroperbenzoic acid (0.0496 g, 0.287 mmol) at 0 ° C., and the temperature was raised to room temperature Stir for 17 hours. To the reaction mixture were added saturated aqueous sodium thiosulfate solution and saturated sodium bicarbonate, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 50 / 50-25 / 75) to give N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl As a white solid]]-4-yl) -1- (3- (methylsulfonyl) propanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 40) (0.0412 g, 0.0773 mmol, 80.6%) Obtained.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.82 (m, 5 H), 2.45-2.48 (m, 1 H), 2.79 (td, J = 11.0, 5.9 Hz, 1 H), 3.06 (s, 3 H), 3.18-3. 27 (m, 2 H), 3. 40 (dt, J = 13.8, 5.5 Hz, 1 H) 3. 77-3.79 (m, 1 H), 3.93-3. 96 (m, 1 H), 5.41 (d, J = 5.4 Hz, 1 H), 7.20 (d, J = 8.5 Hz) , 1 H), 7.30-7.36 (m, 3 H), 7.40-7.44 (m, 1 H), 7.51-7.53 (m, 1 H), 7.86-7.89 (M, 1 H), 8. 28 (br, 1 H).
ESI-MS: m / z = 533 (M + H) ⁺ .

(Reference Example 25) (R)-(3- (2- (2-((2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl Synthesis of tert-butyl) -3-oxopropyl) (methyl) carbamate:

Using 3-((tert-butoxycarbonyl) (methyl) amino) propanoic acid instead of 2-methoxyacetic acid, using the compound of Reference Example 8 instead of the compound of Reference Example 3, and otherwise same as Example 4 The procedure of (R)-(3- (2- (2-((2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) Tert-Butyl 3-oxopropyl) (methyl) carbamate (hereinafter, the compound of Reference Example 25) (0.117 g, 0.201 mmol, 91.5%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.35 (s, 9 H), 1.30-1.77 (m5 H), 2.37-2.80 (m, 3 H), 2.93 ( s, 3 H), 3.18-3. 30 (m, 2 H) 3. 84 (d, J = 13.7 Hz, 1 H), 3.95-4. 03 (m, 1 H), 5. 38-5 .42 (m, 1 H), 7.20 (d, J = 8.3 Hz, 1 H), 7.31-7. 46 (m, 4 H), 7.66-7.72 (m, 1 H), 7 90-7.92 (m, 1 H), 9. 10 (br, 1 H).
ESI-MS: m / z = 584 (M + H) ⁺ .

Example 41 (R) -N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3- (methylamino) propanoyl) Synthesis of piperidine-2-carboxamide:

Using the compound of Reference Example 25 instead of the compound of Reference Example 4, and otherwise the procedure of Reference Example 5 is repeated, (R) -N- (2-chloro-2 '-(trifluoromethoxy)-[ 1,1′-biphenyl] -4-yl) -1- (3- (methylamino) propanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 41) (0.748 g, 0.155 mmol, 77.1) %) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.83 (m, 5 H), 2.47 (s, 3 H), 2.40 to 2.48 (m, 1 H), 2.75 −2.83 (m, 1H), 2.94−2.99 (m, 2H), 3.16 (td, J = 13.1, 2.6 Hz, 1H), 3.88 (d, J = 13.1 Hz, 1 H), 5.41 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.30-7.81 (m, 6 H), 8.80 (br, 1 H).
ESI-MS: m / z = 484 (M + H) ⁺ .

Example 42 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3-hydroxypropanoyl) piperidine-2-carboxamide Synthesis:

N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-) by the same procedure as in Example 4 except for using 3-hydroxypropanoic acid instead of 2-methoxyacetic acid Biphenyl] -4-yl) -1- (3-hydroxypropanoyl) piperidine-2-carboxamide (hereinafter, the compound of Example 42) (0.212 g, 0.450 mmol, 59.9%) was obtained as a white solid. The
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.92 (m, 4 H), 2.35 (d, J = 14.1 Hz, 1 H), 2.64-2.80 (m, m) 2H), 3.06 (t, J = 6.3 Hz, 1 H), 3.19 (td, J = 13.2, 2.4 Hz, 1 H), 3.83 (d, J = 14.1 Hz, 1 H) ), 3.98 (q, J = 5.4 Hz, 2 H), 5. 34 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.0 Hz, 1 H), 7.30 -7.44 (m, 6 H), 7. 7-7. 90 (brm, 1 H), 8. 39 (br, 1 H).
ESI-MS: m / z = 471 (M + H) ^<+> .

Example 43 3- (2-((2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -3-oxo Synthesis of methyl propanoate:

3- (2-((2-chloro-2 '-(trifluoromethoxy)) by the same procedure as in Example 3 except for using methyl 3-chloro-3-oxopropanoate instead of propionyl chloride -[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) methyl 3-oxopropanoate (hereinafter, the compound of Example 43) (0.0500 g, 0.100 mmol, 80.0) %) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.80 (m, 5 H), 2.57-2.62 (m, 1 H), 3.16-3. 25 (m, 1 H) , 3.57 (d, J = 17.2 Hz, 1 H), 3.59-3.65 (m, 1 H), 3.84 (s, 3 H), 3.85 (d, J = 17.2 Hz, 2H), 5.49 (s, 1 H), 7.22 (d, J = 8.2 Hz, 1 H), 7.30 to 7.37 (m, 3 H), 7.40 to 7.44 (m, 5) 1H), 7.92-7.95 (m, 1H), 8.87 (br, 1H).
ESI-MS: m / z = 499 (M + H) ^<+> .

Example 44 4- (2-((2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) -4-oxobutane Synthesis of methyl acid:

4- (2-((2-chloro-2 '-(trifluoromethoxy)-) by the same procedure as in Example 3 except for using methyl 4-chloro-4-oxobutanoate instead of propionyl chloride [1,1′-Biphenyl] -4-yl) carbamoyl) piperidin-1-yl) methyl 4-oxobutanoate (hereinafter, the compound of Example 44) (0.0390 g, 0.0760 mmol, quantitative) as white Obtained as a solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.52-1.60 (m, 5 H), 2.42-2.60 (m, 2 H), 2.62-2.70 (m, 1 H) , 2.88-2.96 (m, 1 H), 2.99-3.08 (m, 1 H), 3.22 (d, J = 14.6 Hz, 1 H), 3.74 (s, 3 H) , 3.97 (d, J = 14.6 Hz, 1 H), 5. 46 (d, J = 5.4 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7.28- 7.44 (m, 6 H), 8. 49 (br, 1 H).
ESI-MS: m / z = 513 (M + H) ^<+> .

Example 45 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3-methoxypropanoyl) piperidine-2-carboxamide Synthesis:

Using the same procedure as Reference Example 2 except for using 1- (3-methoxypropanoyl) piperidine-2-carboxylic acid instead of 1- (tert-butoxycarbonyl) piperidine-2-carboxylic acid, N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (3-methoxypropanoyl) piperidine-2-carboxamide (a compound of Example 45 below) ) (0.0467 g, 0.0963 mmol, 50.6%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.87 (m, 5 H), 2.39 (d, J = 13.9 Hz, 1 H), 2.64 (dt, J = 15. 0, 5.7 Hz, 1 H), 2.85-2.92 (m, 1 H), 3. 14 (td, J = 13.1, 2.3 Hz, 1 H), 3.38 (s, 3 H), 3.67-3.78 (m, 1 H), 3.81-3. 86 (m, 1 H), 3.92 (d, J = 13.9 Hz, 1 H), 5.40 (d, J = 4) .9 Hz, 1 H), 7.21 (d, J = 8.3 Hz, 1 H), 7. 29-7. 80 (m, 6 H), 8. 46 (s, 1 H).
ESI-MS: m / z = 483 (M-H) ^- .

Example 46 N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (1-methyl-1H-pyrazole-4-carbonyl) Synthesis of piperidine-2-carboxamide:

N- (2-chloro-2 ′-(trifluoromethoxy) was carried out according to the procedure as in Example 4, except that 1-methyl-1H-pyrazole-4-carboxylic acid was used instead of 2-methoxyacetic acid. -[1,1'-biphenyl] -4-yl) -1- (1-methyl-1H-pyrazole-4-carbonyl) piperidine-2-carboxamide (hereinafter, the compound of Example 46) (0.0314 g, 0 .0619 mmol, 82.4%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.62-1.71 (m, 2H), 1.78-1.87 (m, 2H), 1.99-2.11 (m, 1H) , 2.37 (d, J = 12.9 Hz, 1 H), 3.08-3.21 (m, 1 H), 3.96 (s, 3 H), 4.13-4.23 (m, 1 H) , 5.18-5.20 (m, 1 H), 7.22 (d, J = 8.3 Hz, 1 H), 7.27-7.90 (m, 6 H), 7. 70 (s, 1 H) , 7.81 (s, 1 H), 9. 18 (br, 1 H).
ESI-MS: m / z = 507 (M + H) ⁺ .

Example 47 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (1-methyl-1H-imidazole-4-carbonyl) Synthesis of piperidine-2-carboxamide:

N- (2-chloro-2 ′-(trifluoromethoxy) is carried out according to the same procedure as in Example 4 except for using 1-methyl-1H-imidazole-4-carboxylic acid instead of 2-methoxyacetic acid -[1,1'-biphenyl] -4-yl) -1- (1-methyl-1H-imidazole-4-carbonyl) piperidine-2-carboxamide (hereinafter, the compound of Example 47) (0.0369 g, 0 .0728 mmol, 96.9%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.45-1.83 (m, 4H), 2.15-2.32 (m, 2H), 2.75-2.87 (m, 1H) , 3.79 (s, 3 H), 4.55-4. 65 (m, 1 H), 5.31-5. 37 (m, 1 H), 7.21 (d, J = 8.3 Hz, 1 H) , 7.31-7.63 (m, 7H), 7.75-7.90 (m, 1 H), 11. 47 (br, 1 H).
ESI-MS: m / z = 507 (M + H) ⁺ .

Example 48 N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (1H-pyrazole-4-carbonyl) piperidine-2- Carboxamide Synthesis:

The procedure is as in Example 4, but using 1H-pyrazole-4-carboxylic acid instead of 2-methoxyacetic acid, to obtain N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1 1′-biphenyl] -4-yl) -1- (1H-pyrazole-4-carbonyl) piperidine-2-carboxamide (hereinafter compound of Example 48) (0.0163 g, 0.0331 mmol, 44.0%) Was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.45-1.90 (m, 4 H), 1.95-2.17 (m, 1 H), 2.33-2.43 (m, 1 H) , 3.15-3.26 (m, 1 H), 4.09-4. 21 (m, 1 H), 5.20-5. 27 (m, 1 H), 7.22 (d, J = 8. 5 Hz, 1 H), 7.28-7. 52 (m, 5 H), 7. 70-8.00 (m, 3 H), 9. 16 (br, 1 H), 10. 79 (br, 1 H).
ESI-MS: m / z = 493 (M + H) ⁺ .

Reference Example 26 Synthesis of methyl 1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxylate:

A compound of Reference Example 20 is used instead of 2-methoxyacetic acid, methyl piperidine-2-carboxylate hydrochloride is used instead of the compound of Reference Example 3, and the procedure is the same as that of Example 4 except that 1- ( Methyl 2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxylate (hereinafter, the compound of Reference Example 26) (0.934 g, 3.19 mmol, 82.0) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.24-1.76 (m, 5 H), 2.25-2.32 (m, 1 H), 2.99 (s, 3 H), 3.00 (S, 3H), 3.25 (td, J = 13.0, 3.2 Hz, 1 H), 3.58-3.64 (m, 1 H), 3.75 (d, J = 4.6 Hz, 3H), 4.11 (d, J = 17.1 Hz, 1 H), 4.30 (d, J = 17.1 Hz, 1 H), 5.25 (d, J = 5.6 Hz, 1 H).
ESI-MS: m / z = 293 (M + H) ⁺ .

Reference Example 27 Synthesis of 1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxylic acid:

To a solution of the compound of Reference Example 26 (0.933 g, 3.19 mmol) in methanol (10.0 mL) was added 1 M aqueous sodium hydroxide solution (3.83 mL, 3.83 mmol) at 0 ° C., and the temperature was raised to room temperature 17 Stir for hours. The reaction solution was added with 1 M hydrochloric acid and extracted with chloroform. The organic layer is washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give crude 1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxylic acid (below) The compound of Reference Example 27 (0.812 g) was obtained as a white solid. The compound of Reference Example 27 was used as it was in the next reaction.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.18-1.75 (m, 5 H), 2.30 (d, J = 13.1 Hz, 1 H), 2.98 (s, 3 H), 2 .99 (s, 3H), 3.24 (t, J = 12.0 Hz, 1 H), 3.63 (d, J = 13.1 Hz, 1 H), 4.13 (d, J = 17.2 Hz, 1H), 4.27 (d, J = 17.2 Hz, 1 H), 5.24 (d, J = 4.1 Hz, 1 H).
ESI-MS: m / z = 279 (M + H) ⁺ .

Reference Example 28 Synthesis of N- (4-bromo-3-chlorophenyl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide:

The compound of Reference Example 27 is used in place of 1- (tert-butoxycarbonyl) piperidine-2-carboxylic acid, 4-bromo-3-chloroaniline is used in place of the compound of Reference Example 1, and Reference Example 2 is otherwise obtained. N- (4-Bromo-3-chlorophenyl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide (hereinafter referred to as the compound of Reference Example 28) (0. 296 g, 0.634 mmol, 58.8%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.49-1.85 (m, 5 H), 2.34 (d, J = 12.8 Hz, 1 H), 3.03 (s, 3 H), 3 .03 (s, 3H), 3.20 (t, J = 12.8 Hz, 1 H), 3.71 (d, J = 12.8 Hz, 1 H), 4.12 (d, J = 16.7 Hz, 1H), 4.23 (d, J = 16.7 Hz, 1 H), 5.22 (d, J = 4.9 Hz, 1 H), 7.20-7.24 (m, 1 H), 7.50 ( dd, J = 8.5, 2.0 Hz, 1 H), 7.84 (t, J = 2.3 Hz, 1 H), 8.20 (br, 1 H).
ESI-MS: m / z = 467 (M + H) ^<+> .

Example 49 N- (2-Chloro-2′-isopropoxy- [1,1′-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2 -Synthesis of carboxamide:

Procedure similar to Reference Example 1 except for using 2-isopropoxyphenylboronic acid instead of 2-trifluoromethoxyphenylboronic acid and the compound of Reference Example 28 instead of 4-bromo-3-chloroaniline N- (2-chloro-2′-isopropoxy- [1,1′-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide Thereafter, the compound of Example 49 (0.0253 g, 0.0485 mmol, 75.3%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.20 (d, J = 6.0 Hz, 6 H), 1.50-1.88 (m, 5 H), 2.31-2.39 (m, 1H), 3.05 (s, 3 H), 3.05 (s, 3 H), 3.21-3.28 (m, 1 H), 3.69-3.74 (m, 1 H), 4.19 (D, J = 16.8 Hz, 1 H), 4. 25 (d, J = 16.8 Hz, 1 H), 4.41 (t, J = 6.0 Hz, 1 H), 5.23-5.26 ( m, 1 H), 6.95-7.00 (m, 2 H), 7. 17 (dd, J = 7.4, 2.0 Hz, 1 H), 7.22-7.37 (m, 3 H), 7.76 (d, J = 2.0 Hz, 1 H), 8.11 (s, 1 H).
ESI-MS: m / z = 523 (M + H) ⁺ .

Example 50 N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (2- (1-methyl-1H-imidazole-2) Synthesis of (yl) acetyl) piperidine-2-carboxamide:

The procedure was as in Example 4 except that 2- (1-methyl-1H-imidazol-2-yl) acetic acid was used instead of 2-methoxyacetic acid, and the procedure was as in Example 4 to obtain N- (2-chloro-2 ′-( Trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (1-methyl-1H-imidazol-2-yl) acetyl) piperidine-2-carboxamide (Example 50 below) (0.0341 g, 0.0654 mmol, 87.0%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.49-1 to 80 (m, 5 H), 2.67 to 2. 74 (m, 1 H), 3.20 to 3. 27 (m, 1 H) , 3.54-3.62 (m, 1 H), 3.63 (s, 3 H), 3.73 (d, J = 15.9 Hz, 1 H), 4.05 (d, J = 15.9 Hz, 1H), 5.59-5.63 (m, 1 H), 6.89-6.98 (m, 2 H), 7.20-7. 29 (m, 1 H), 7.32-7. m, 3H), 7.39-7.45 (m, 1 H), 7.71-7.99 (m, 2 H), 10. 64 (br, 1 H).
ESI-MS: m / z = 521 (M + H) ⁺ .

Reference Example 29 Synthesis of N- (4-bromo-3-fluorophenyl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide:

The compound of Reference Example 27 is used in place of 1- (tert-butoxycarbonyl) piperidine-2-carboxylic acid, 4-bromo-3-fluoroaniline is used in place of the compound of Reference Example 1, and Reference Example 2 is otherwise obtained. N- (4-bromo-3-fluorophenyl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide (the compound of Reference Example 29) (0 .0253 g, 0.0562 mmol, 52.1%) were obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.48-1.83 (m, 5 H), 2.31-2. 39 (m, 1 H), 3.03 (s, 3 H), 3.03 (S, 3 H), 3.16-3. 23 (m, 1 H), 3. 6-8. 75 (m, 1 H), 4. 10 (d, J = 16.6 Hz, 1 H), 4.24 (D, J = 16.6 Hz, 1 H), 5.21-5. 24 (m, 1 H), 7.06 (dd, J = 9.0, 2.0 Hz, 1 H), 7.43 (t, J = 8.2 Hz, 1 H), 7.63 (dd, J = 10.5, 2.4 Hz, 1 H), 8.24 (br, 1 H).
ESI-MS: m / z = 451 (M + H) ⁺ .

Example 51 N- (2-Fluoro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfonamido) acetyl) Synthesis of piperidine-2-carboxamide:

Using the compound of Reference Example 29 instead of 4-bromo-3-chloroaniline and following the same procedure as Reference Example 1 except for N- (2-fluoro-2 '-(trifluoromethoxy)-[1 , 1′-biphenyl] -4-yl) -1- (2- (N-methylmethylsulfonamido) acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 51) (0.0132 g, 0.0248 mmol, 44.7%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.45-1.90 (m, 5 H), 2.33-2.41 (m, 1 H), 3.05 (s, 6 H), 3.20 -3. 29 (m, 1 H), 3.69-3. 76 (m, 1 H), 4. 17 (d, J = 16.8 Hz, 1 H), 4. 25 (d, J = 16.8 Hz, 1H), 5.23-5.27 (m, 1H), 7.20-7.44 (m, 6H), 7.62 (dd, J = 11.7, 2.0 Hz, 1H), 8. 24 (br, 1 H).

(Example 52) 1- (2- (1H-imidazol-1-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl ) Synthesis of piperidine-2-carboxamide:

A procedure similar to that of Example 4 except that 1-imidazoleacetic acid is used instead of 2-methoxyacetic acid, to give 1- (2- (1H-imidazol-1-yl) acetyl) -N- (2-chloro) -2 '-(Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 52) (0.0189 g, 0.0373 mmol, 49.6% ) As a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.44-2.05 (m, 5 H), 2.23-2.31 (m, 1 H), 3.37-3. 47 (m, 1 H) , 3.67-3.74 (m, 1 H), 4.86 (d, J = 16.6 Hz, 1 H), 4.91 (d, J = 16.6 Hz, 1 H), 5.16-5. 22 (m, 1 H), 6.97 (s, 1 H), 7. 13 (s, 1 H), 7. 20 (d, J = 8.3 Hz, 1 H), 7.29-7.37 (m, 4H), 7.40-7.45 (m, 1 H), 7.53 (s, 1 H), 7. 7-7. 87 (m, 1 H), 8.41 (br, 1 H).
ESI-MS: m / z = 507 (M + H) ⁺ .

Example 53 1- (2- (1H-tetrazol-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl ) Synthesis of piperidine-2-carboxamide:

The procedure is as in Example 4, except that 1H-tetrazole-1-acetic acid is used instead of 2-methoxyacetic acid, to obtain 1- (2- (1H-tetrazol-1-yl) acetyl) -N- ( 2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 53) (0.0244 g, 0.0479 mmol, 38 .2%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.59-2.02 (m, 5 H), 2.29-2.32 (m, 1 H), 3.49-3. 57 (m, 1 H) , 3.73-3.77 (m, 1 H), 5.18-5.19 (m, 1 H), 5.40 (d, J = 16.8 Hz, 1 H), 5.48 (d, J = 16.8 Hz, 1 H), 7.21-7. 46 (m, 6 H), 7.81 (br, 1 H), 8.02 (s, 1 H), 8.86 (s, 1 H).
ESI-MS: m / z = 509 (M + H) ⁺ .

Example 54 1- (2- (furan-2-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine Synthesis of -2-carboxamide:

A procedure similar to that of Example 4 except that 2-furanacetic acid is used instead of 2-methoxyacetic acid, to give 1- (2- (furan-2-yl) acetyl) -N- (2-chloro-2 '-(Trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 54) (0.0605 g, 0.119 mmol, 95.2%) Obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.41-1.95 (m, 5 H), 2.33-2.38 (m, 1 H), 3.08-3. 16 (m, 1 H) , 3.85-3.97 (m, 3H), 5.34-5.36 (m, 1H), 6.22-6.23 (m, 1H), 6.35-6. 37 (m, 1H), 7.19-7.44 (m, 8H), 8.33 (br, 1H).
ESI-MS: m / z = 505 (M-H) ^- .

Example 55 1- (2- (3,5-Dimethyl-1H-pyrazol-1-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'- Synthesis of biphenyl] -4-yl) piperidine-2-carboxamide:

The procedure is as in Example 4 except that 3,5-dimethyl-1H-pyrazole-1-acetic acid is used instead of 2-methoxyacetic acid, and 1- (2- (3,5-dimethyl-1H-) Pyrazol-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter referred to as Example 55) Compound (0.0579 g, 0.108 mmol, 86.3%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.66 (m, 2 H), 1.74-1. 79 (m, 3 H), 2.08 (s, 3 H), 2.27 (S, 3 H), 2.47-2. 50 (m, 1 H), 3.11-3. 19 (m, 1 H), 3.69- 3. 74 (m, 1 H), 4.83 (d , J = 15.2 Hz, 1H), 4.96 (d, J = 15.2 Hz, 1 H), 5.35-5.36 (m, 1 H), 5.89 (s, 1 H), 7.21. -7.45 (m, 7H), 8.86 (br, 1H).
ESI-MS: m / z = 535 (M + H) ⁺ .

Example 56 1- (2- (3-Methylisoxazol-5-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4 Synthesis of (yl) piperidine-2-carboxamide:

1- (2- (3-Methylisoxazol-5-yl) acetyl) in the same manner as in Example 4 except for using 3-methyl-5-isoxazole acetic acid instead of 2-methoxyacetic acid -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 56) (0.0652 g, 0 .125 mmol, 99.6%) were obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.47-1.96 (m, 5 H), 2.29 (s, 3 H), 2.33-2.39 (m, 1 H), 3.21 -3. 28 (m, 1 H), 3.82-3. 87 (m, 1 H), 3.95 (d, J = 16.1 Hz, 1 H), 4.01 (d, J = 16.1 Hz, 1H), 5.32-5.33 (m, 1 H), 6.08 (s, 1 H), 7.21-7. 45 (m, 7 H), 8.27 (br, 1 H).
ESI-MS: m / z = 520 (M-H) ^- .

Example 57 (R) -1- (2- (1H-tetrazol-1-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] Synthesis of 4-yl) piperidine-2-carboxamide:

A solution of the compound of Reference Example 8 (4.00 g, 10.03 mmol) in DMF (10 mL), HATU (4. 96 g) in a solution of 1 H-tetrazole-1-acetic acid (1.67 g, 13.04 mmol) in DMF (30 mL) , 13.04 mmol) and diisopropylethylamine (2.63 mL, 15.04 mmol) were added at room temperature and stirred at the same temperature for 17 hours. Distilled water was added to the reaction solution, extraction was performed with toluene, and the organic layer was concentrated under reduced pressure. The residue is purified by column chromatography (amine silica gel, n-hexane / ethyl acetate = 40/60 to 0/100), and (R) -1- (2- (1H-tetrazol-1-yl) acetyl) -N -(2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 57) (3.87 g, 7.60 mmol) (75.9%) was obtained as a white amorphous. When analysis using a chiral column, the retention time of the obtained compound of Example 57 was 55.3 minutes, and the optical purity at that time was 99.4% ee. The analysis conditions using a chiral column are as follows.
Measuring equipment; Shimadzu Corporation High-performance liquid chromatograph LC-2010CHT
Column; Daicel Chemical Industries, Ltd. CHIRALCEL OD-RH 0.46 cmφ × 15 cm particle diameter 5 μm
Column temperature: 40 ° C
Mobile phase; (Liquid A) Distilled water, (Liquid B) Composition of acetonitrile mobile phase; Liquid A: Liquid B = 60: 40 (0 to 75 minutes).
Flow rate: 0.5 mL / min detection; UV (210 nm)
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.62 to 2.00 (m, 5 H), 2.27 to 2. 31 (m, 1 H), 3.52 to 3.58 (m, 1 H) , 3.73-3.76 (m, 1 H), 5.18-5.19 (m, 1 H), 5.40 (d, J = 16.5 Hz, 1 H), 5.48 (d, J = 16.5 Hz, 1 H), 7.21-7. 45 (m, 6 H), 7.81 (br, 1 H), 8. 15 (s, 1 H), 8.86 (s, 1 H).
ESI-MS: m / z = 509 (M + H) ⁺ .

Example 58 (R) -1- (3- (1H-tetrazol-1-yl) propanoyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] Synthesis of 4-yl) piperidine-2-carboxamide:

Using 3- (tetrazol-1-yl) propionic acid instead of 2-methoxyacetic acid, using the compound of Reference Example 8 instead of the compound of Reference Example 3, and using the same procedure as Example 4 except that ( R) -1- (3- (1H-tetrazol-1-yl) propanoyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine -2-carboxamide (hereinafter, the compound of Example 58) (0.117 g, 0.224 mmol, 89.1%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.43-1.97 (m, 5 H), 2.25-2.29 (m, 1 H), 3.04-3. 19 (m, 2 H) , 3.25 (td, J = 13.0, 2.7 Hz, 1 H) 3.70-3.74 (m, 1 H), 4.79-4.92 (m, 2 H), 5.18-5 19 (m, 1 H), 7.22-7.44 (m, 6 H), 7.79 (br, 1 H), 8.13 (br, 1 H), 8.84 (s, 1 H).
ESI-MS: m / z = 521 (M-H) ^- .

Example 59 (R) -1- (3- (1H-Imidazol-1-yl) propanoyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] Synthesis of 4-yl) piperidine-2-carboxamide:

Using 3- (imidazol-1-yl) propionic acid instead of 2-methoxyacetic acid, using the compound of Reference Example 8 instead of the compound of Reference Example 3, and using the same procedure as Example 4 except that R) -1- (3- (1H-imidazol-1-yl) propanoyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine -2-carboxamide (hereinafter, the compound of Example 59) (0.0799 g, 0.153 mmol, 60.9%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.37 to 1.99 (m, 5 H), 2.26 to 2.29 (m, 1 H), 2.87 to 2.91 (m, 2 H) , 3.17 (td, J = 13.3, 2.7 Hz, 1 H) 3.67-3. 71 (m, 1 H), 4.34-4. 47 (m, 2 H), 5.24-5 25 (m, 1 H), 6.99 (s, 1 H), 7.06 (s, 1 H), 7.21-7. 45 (m, 6 H), 7.58 (br, 1 H), 7. 71-7.82 (m, 1 H), 8.33 (br, 1 H).
ESI-MS: m / z = 521 (M + H) ⁺ .

Example 60 (R) -1- (3- (3-Methyl-1H-pyrazol-1-yl) propanoyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1 Synthesis of '-biphenyl] -4-yl) piperidine-2-carboxamide:

Using 3- (3-methyl-pyrazol-1-yl) propionic acid instead of 2-methoxyacetic acid, using the compound of Reference Example 8 instead of the compound of Reference Example 3 and using the same method as Example 4 except the above. According to the procedure (R) -1- (3- (3-Methyl-1H-pyrazol-1-yl) propanoyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'- Biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 60) (0.135 g, 0.252 mmol, quantitative) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.37-1.89 (m, 5 H), 2.12 (s, 3 H), 2.35-2.38 (m, 1 H), 2.85 -3.12 (m, 3 H), 3.67-3. 70 (m, 1 H), 4. 38-4. 44 (m, 1 H), 4.5 1-4. 58 (m, 1 H), 5 30. -5. 32 (m, 1 H), 5.96-5.97 (m, 1 H), 7. 19-7. 45 (m, 8 H), 8.59 (br, 1 H).
ESI-MS: m / z = 535 (M + H) ⁺ .

Example 61 (R) -1- (2- (1H-Pyrazole-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] Synthesis of 4-yl) piperidine-2-carboxamide:

Using 2- (1H-pyrazol-1-yl) acetic acid instead of 2-methoxyacetic acid, using the compound of Reference Example 8 instead of the compound of Reference Example 3, and following the same procedure as Example 4 (R) -1- (2- (1H-pyrazol-1-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) Piperidine-2-carboxamide (hereinafter, the compound of Example 61) (0.0623 g, 0.123 mmol, 98.0%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.74 (m, 5 H), 2.52 to 2.55 (m, 1 H), 3.04 to 3.12 (m, 1 H) , 3.65-3.69 (m, 1H), 5.01 (d, J = 14.5 Hz, 1 H), 5.22 (d, J = 14.5 Hz, 1 H), 5.43-5. 44 (m, 1 H), 6.39 (dd, J = 2.3, 2.0 Hz, 1 H), 7.24 (d, J = 8.2 Hz, 1 H), 7.32-7.37 (m , 3H), 7.41-7.45 (m, 1 H), 7.52-7.61 (m, 1 H), 7.53 (d, J = 2.3 Hz, 1 H), 7.58 (d , J = 2.0 Hz, 1 H), 7.80-7.87 (brm, 1 H), 9.02 (s, 1 H).
ESI-MS: m / z = 507 (M + H) ⁺ .

(Example 62) (R) -1- (2- (4H-1,2,4-triazol-4-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1 Synthesis of 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide:

Using 2- (4H-1,2,4-triazol-4-yl) acetic acid instead of 2-methoxyacetic acid, and using the compound of Reference Example 8 instead of the compound of Reference Example 3, and Example 4 otherwise Similar procedures as in (R) -1- (2- (4H-1,2,4-triazol-4-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[ 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 62) (0.0575 g, 0.113 mmol, 90.3%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.55-1.90 (m, 5 H), 2.29-2.32 (m, 1 H), 3.57-3. 71 (m, 2 H) , 4.93 (d, J = 16.8 Hz, 1 H), 5.02 (d, J = 16.8 Hz, 1 H), 5.22-5.23 (m, 1 H), 7.19 (d, J = 8.2 Hz, 1 H), 7.28-7.37 (m, 4 H), 7.40-7. 45 (m, 1 H), 7.81 (s, 1 H), 8.21 (s, 1 H) 2H), 8.84 (s, 1H).
ESI-MS: m / z = 508 (M + H) ⁺ .

Example 63 (R) -1- (2- (1H-1,2,4-triazol-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1 Synthesis of 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide:

Sodium 2- (1H-1,2,4-triazol-1-yl) acetate instead of 2-methoxyacetic acid, the compound of Reference Example 8 instead of the compound of Reference Example 3, and the other examples A procedure similar to 4 gives (R) -1- (2- (1H-1,2,4-triazol-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)- [1,1′-Biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 63) (0.0587 g, 0.116 mmol, 92.2%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.54-1.70 (m, 2H), 1.77-1.90 (m, 3H), 2.38-2.41 (m, 1H) , 3.31-3.39 (m, 1 H), 3.74-3. 78 (m, 1 H), 5.13 (d, J = 15.4 Hz, 1 H), 5.22 (d, J = 15.4 Hz, 1 H), 5. 29 (d, J = 5.0 Hz, 1 H), 7.23 (d, J = 8.2 Hz, 1 H), 7.30-7.37 (m, 4 H), 7.41-7.45 (m, 1 H), 7.79 (brs, 1 H), 8.02 (s, 1 H), 8.26 (s, 1 H), 8.39 (s, 1 H).
ESI-MS: m / z = 508 (M + H) ⁺ .

Example 64 (R) -1- (2- (1H-1,2,3-Triazol-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1 Synthesis of 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide:

Instead of 2-methoxyacetic acid, 2- (1H-1,2,3-triazol-1-yl) acetic acid is used, and instead of the compound of Reference Example 3, the compound of Reference Example 8 is used, and Example 4 is otherwise obtained. By a procedure similar to that of (R) -1- (2- (1H-1,2,3-triazol-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[ 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 64) (0.0619 g, 0.122 mmol, 97.2%) was obtained as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.51 to 1.70 (m, 2H), 1.76 to 1.88 (m, 3H), 2.39 to 2.42 (m, 1H) , 3.32-3.39 (m, 1H), 3.74-3.78 (m, 1H), 5.30-5.31 (m, 1H), 5.34 (d, J = 15. 4 Hz, 1 H), 5.41 (d, J = 15.4 Hz, 1 H), 7.23 (d, J = 8.6 Hz, 1 H), 7.30-7.37 (m, 3 H), 7. 41-7.45 (m, 1 H), 7.52 (brs, 1 H), 7.76 (d, J = 0.9 Hz, 1 H), 7.82 (d, J = 0.9 Hz, 1 H), 7.91 (brs, 1 H), 8.43 (s, 1 H).
ESI-MS: m / z = 508 (M + H) ⁺ .

Example 65 (R) -1- (2- (1H-Imidazol-1-yl) acetyl) -N- (2-chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] Synthesis of 4-yl) piperidine-2-carboxamide:

(R) -1- (2) was prepared by the same procedure as in Example 4 except that 1-imidazoleacetic acid was used instead of 2-methoxyacetic acid, and the compound of Reference Example 8 was used instead of the compound of Reference Example 3. -(1H-imidazol-1-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) piperidine-2-carboxamide (in the following, The compound of Example 65 (0.635 g, 1.25 mmol, 63.5%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.44-2.05 (m, 5 H), 2.23-2.31 (m, 1 H), 3.37-3. 47 (m, 1 H) , 3.67-3.74 (m, 1 H), 4.86 (d, J = 16.6 Hz, 1 H), 4.91 (d, J = 16.6 Hz, 1 H), 5.16-5. 22 (m, 1 H), 6.97 (s, 1 H), 7. 13 (s, 1 H), 7. 20 (d, J = 8.3 Hz, 1 H), 7.29-7.37 (m, 4H), 7.40-7.45 (m, 1 H), 7.53 (s, 1 H), 7. 7-7. 87 (m, 1 H), 8.41 (brs, 1 H).
ESI-MS: m / z = 507 (M + H) ⁺ .

(Example 66) (R) -1- (2- (2H-1,2,3-triazol-2-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[1 Synthesis of 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide:

Using 2- (2H-1,2,3-triazol-2-yl) acetic acid instead of 2-methoxyacetic acid, and using the compound of Reference Example 8 instead of the compound of Reference Example 3, and Example 4 otherwise By a procedure similar to that of (R) -1- (2- (2H-1,2,3-triazol-2-yl) acetyl) -N- (2-chloro-2 '-(trifluoromethoxy)-[ 1,1′-biphenyl] -4-yl) piperidine-2-carboxamide (hereinafter, the compound of Example 66) (0.0321 g, 0.0632 mmol, 50.4%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.47-1.65 (m, 2H), 1.68-1.77 (m, 3H), 2.49-2.52 (m, 1H) , 2.98-3.06 (m, 1 H), 3.55-3. 58 (m, 1 H), 5.33 (d, J = 15.0 Hz, 1 H), 5.42 (d, J = 5.0 Hz, 1H), 5.57 (d, J = 15.0 Hz, 1 H), 7.24 (d, J = 8.2 Hz, 1 H), 7.32-7.37 (m, 3 H), 7.41-7.46 (m, 1 H), 7.42-7.88 (brm, 2 H), 7.73 (s, 2 H), 8.63 (s, 1 H).
ESI-MS: m / z = 530 (M + Na) ⁺ .

Reference Example 30 Synthesis of ethyl 2- (5-methyl-1,3,4-oxadiazol-2-yl) acetate:

Acetic anhydride (0.393 mL, 4.16 mmol) is added at room temperature to a solution of ethyl 2- (1H-tetrazol-5-yl) acetate (0.500 g, 3.20 mmol) in dichloroethane (100 mL). The mixture was stirred for 11 hours after the temperature rise. To the reaction mixture was added 1 M aqueous sodium hydroxide solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with 1 M aqueous sodium hydroxide solution and saturated brine, then dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, n-hexane / ethyl acetate = 70/30 to 40/60) and ethyl 2- (5-methyl-1,3,4-oxadiazol-2-yl) acetate (The compound of Reference Example 30 below (0.0908 g, 0.534 mmol, 16.7%) was obtained as a colorless oil.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.29 (t, J = 7.2 Hz, 3 H), 2.55 (s, 3 H), 3.92 (s, 2 H), 4.23 (q) , J = 7.2 Hz, 2 H).
ESI-MS: m / z = 171 (M + H) ⁺ .

Reference Example 31 Synthesis of sodium 2- (5-methyl-1,3,4-oxadiazol-2-yl) acetate:

To a solution of the compound of Reference Example 30 (0.0900 g, 0.529 mmol) in tetrahydrofuran (1.0 mL), 1 M aqueous sodium hydroxide solution (1.06 mL, 1.06 mmol) and ethanol (1.0 mL) are added at room temperature, The mixture was stirred at the same temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to give crude sodium 2- (5-methyl-1,3,4-oxadiazol-2-yl) acetate (hereinafter, the compound of Reference Example 31) (0.0835 g) as a white solid. The The compound of Reference Example 31 was used as it was in the next reaction.
¹ H-NMR (400 MHz, DMSO-D ₆ ) δ: 2.41 (s, 3 H), 3.38 (s, 2 H).
ESI-MS: m / z = 143 (M + H) ⁺ .

Example 67 (R) -N- (2-Chloro-2 ′-(trifluoromethoxy)-[1,1′-biphenyl] -4-yl) -1- (2- (5-methyl-1) Synthesis of (3,4-Oxadiazol-2-yl) acetyl) piperidine-2-carboxamide:

Using the compound of Reference Example 31 instead of 2-methoxyacetic acid, and using the compound of Reference Example 8 instead of the compound of Reference Example 3, and otherwise the procedure of Example 4 is repeated to obtain (R) -N- (R). 2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (2- (5-methyl-1,3,4-oxadiazol-2-yl) )) Acetyl) piperidine-2-carboxamide (hereinafter, the compound of Example 67) (0.0524 g, 0.0910 mmol, 90.8%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.50-1.66 (m, 3 H), 1.74-1. 77 (m, 2 H), 2.57 (s, 3 H), 2.62 -2.65 (m, 1H), 3.27-3.34 (m, 1H), 3.61-3.64 (m, 1H), 3.94 (d, J = 17.4 Hz, 1H) , 4.21 (d, J = 17.4 Hz, 1 H), 5.54-5. 55 (m, 1 H), 7.25-7.27 (m, 1 H), 7.33-7. 36 ( m, 3H), 7.40-7.44 (m, 1 H), 7.77 (brs, 1 H), 8. 18 (brs, 1 H), 9. 38 (s, 1 H).
ESI-MS: m / z = 545 (M + Na) ⁺ .

Example 68 (R) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (3- (dimethylamino) propanoyl) Synthesis of piperidine-2-carboxamide:

Using the same procedure as in Example 4 except for using 3- (dimethylamino) propanoic acid hydrochloride instead of 2-methoxyacetic acid and the compound of Reference Example 8 instead of the compound of Reference Example 3 (R ) -N- (2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) -1- (3- (dimethylamino) propanoyl) piperidine-2-carboxamide (infra) Compound of Example 68 (0.0826 g, 0.166 mmol, 66.2%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.46 to 1.83 (m, 5 H), 2.26 (s, 0.6 H), 2.28 (s, 5.4 H), 2.40 -2.44 (m, 1 H), 2.55-2.62 (m, 1 H), 2.65-2.81 (m, 3 H), 2.99-3.05 (m, 0.1 H) , 3.13-3.20 (m, 0.9 H), 3.88-3. 91 (m, 0.9 H), 4.69 (d, J = 5.0 Hz, 0.1 H), 4. 73-4.76 (m, 0.1 H), 5.43 (d, J = 5.0 Hz, 0.9 H), 7.21 (d, J = 8.6 Hz, 1 H), 7.31-7 86 (m, 6 H), 8. 76 (br, 0.9 H), 9.33 (br, 0.1 H).
ESI-MS: m / z = 498 (M + H) ⁺ .

(Example 69) (R) -5- (2- (2-((2-chloro-2 '-(trifluoromethoxy)-[1, 1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) Synthesis of methyl -5-oxopentanoate:

Using methyl 4- (chloroformyl) butyrate instead of propionyl chloride, substituting the compound of Reference Example 8 instead of the compound of Reference Example 3, and otherwise using the same procedure as Example 3, (R) -5- (2-((2-Chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) methyl 5-oxopentanoate The compound of Example 69) (0.130 g, 0.247 mmol, 98.4%) was obtained as a white amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.44-1.79 (m, 4 H), 1.84-1. 95 (m, 1 H), 1.96-2.13 (m, 2 H) , 2.35 (d, J = 13.7 Hz, 1 H), 2.40-2.62 (m, 4 H), 2.63-2.70 (m, 0.1 H), 3.14-3. 21 (m, 0.9 H), 3.68 (s, 2.7 H), 3.69 (s, 0.3 H), 3.84-3. 88 (m, 0.9 H), 4.66- 4.69 (m, 0.2 H), 5.34 (d, J = 5.0 Hz, 0.9 H), 7.20 (d, J = 8.2 Hz, 1 H), 7.29-7.94 (M, 6H), 8.68 (s, 0.9 H), 8. 90 (s, 0.1 H).

(Example 70) (R) -5- (2- (2-((2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl] -4-yl) carbamoyl) piperidin-1-yl) Synthesis of -5-oxopentanoic acid:

To a solution of the compound of Example 69 (0.130 g, 0.247 mmol) in methanol (2.5 mL) was added 1 M aqueous sodium hydroxide solution (2.47 mL, 2.47 mmol) and tetrahydrofuran (2.5 mL) at 0 ° C. After heating to room temperature, the mixture was stirred for 5 hours. The reaction solution was added with 1 M hydrochloric acid and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, chloroform / methanol = 98/2 to 90/10) to give (R) -5- (2-((2-chloro-2 '-(trifluoromethoxy)-[1 (1′-biphenyl) -4-yl) carbamoyl) piperidin-1-yl) -5-oxopentanoic acid (hereinafter compound of Example 70) (0.0592 g, 0.115 mmol, 46.7%) to a white color Obtained as amorphous.
¹ H-NMR (400 MHz, CDCl ₃ ) δ: 1.49-1 to 79 (m, 4 H), 1.84-1.94 (m, 1 H), 2.00 to 2. 10 (m, 2 H) , 2.32 (d, J = 13.6 Hz, 1 H), 2.44-2.63 (m, 4 H), 3. 20 (td, J = 13.3, 2.6 Hz, 1 H), 3. 81-3.87 (m, 1H), 5.30 (d, J = 4.5 Hz, 1 H), 7.20 (d, J = 8.6 Hz, 1 H), 7.29-7.36 (m , 3H), 7.40-7.45 (m, 2H), 7.75-7.88 (m, 1 H), 8.62 (s, 1 H).
ESI-MS: m / z = 535 (M + Na) ⁺ .

(Example 71) RORγ-coactivator binding inhibitory action:
Time-resolved fluorescence energy transfer (TR-) of the inhibitory effect of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on the binding of the ligand binding domain of RORγ (hereinafter referred to as RORγ-LBD) to the coactivator was evaluated using the LanthaScreen using ^{FRET) TM TR-FRET Retinoid-} Related Orphan Receptor (ROR) gamma Coactivator Assay kit (invitrogen, Inc.).

The test compound was dissolved in DMSO and then diluted with a 5 mmol / L DTT-containing TR-FRET Coregulator Buffer D (invitogen) to a final DMSO concentration of 1%. To each well of a 384 well black plate (Corning), 4 nmol / L GST-fused RORγ-LBD (invitogen) diluted with the above buffer and a test compound were added. A test compound-free and GST-fused RORγ-LBD-free (background), and a test compound-free and GST-fused RORγ-LBD-added (control) wells were provided. Next, 150 nmol / L Flurescein-labeled TRAP220 / DRIP-2 (invitogen) diluted with the above buffer and 32 nmol / L terbium-labeled anti-GST antibody (invitogen) were added to each well. After incubating the plate at room temperature for 16 to 24 hours, the fluorescence at 495 nm and 520 nm when excited at 320 nm was measured for each well, and the Ratio (fluorescence at 520 nm / fluorescence at 495 nm) was calculated.

Fold change at the time of test compound addition (Ratio at the time of test compound addition / Ratio of background), Fold change of control (Ratio of control / Ratio of background), and Fold change of background (Ratio of background / background) After calculating the ratio of the ground, the binding inhibition rate of RORγ-LBD and the coactivator (hereinafter, RORγ-coactivator binding inhibition rate) (%) was calculated from the following equation 1.

RORγ-coactivator binding inhibition rate (%) = (1 − ((Fold change upon addition of test compound) − (Fold change)) / ((Fold change) − (Fold change) )) × 100 ··· Formula 1

The RORγ-coactivator binding inhibition rate (%) at 33 μmol / L of the test compound is shown in Table 2-1 and Table 2-2.

From this result, it was revealed that cyclic amine derivative (I) or a pharmacologically acceptable salt thereof significantly inhibits the binding of RORγ-LBD to a coactivator.

(Example 72) Inhibitory effect on IL-17 production in mouse splenocytes:
The suppression effect of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on IL-23 production by IL-23 stimulation using mouse splenocytes is shown in The Journal of Biological Chemistry, 2003, vol. 278. , No. 3, p. The method described in 1910-1914 was partially modified and evaluated.

A single cell suspension was prepared from the spleen of a C57BL / 6J mouse (male, 7-23 weeks old) (Charles River Japan, Inc.), and splenocytes were prepared using Histopaque-1083 (Sigma). The culture medium is RPMI 1640 medium (Gibco), 10% FBS (Gibco), 50 U / mL penicillin, 50 μg / mL streptomycin (Gibco), 50 μmol / L 2-mercaptoethanol (Gibco) and 100 U / mL human IL- 2 (Cell Science Research Institute, Inc.) was added and used. The test compound was dissolved in DMSO and then diluted to a final concentration of 0.1% in culture medium. Splenocytes (3 × 10 ⁵ cells / well) prepared in culture medium are seeded in wells of a 96 well flat bottom plate (Corning Co.), and a test compound and 10 ng / mL of human IL-23 (R & D systems) are added. The cells were cultured at 37 ° C. and 5% CO ₂ for 3 days. In addition, a human IL-23 non-added and a test compound non-added, and a human IL-23 added and test compound non-added well were provided. After completion of the culture, the culture supernatant was collected, and the amount of IL-17 produced in the supernatant was quantified by ELISA (R & D systems).

The IL-17 production suppression rate (%) was calculated from the following formula 2.

IL-17 production suppression rate (%) = (1- ((IL-23 production amount with addition of IL-23 and test compound))-(IL-17 production amount without IL-23 addition and without test compound) )) / ((The amount of IL-17 produced with addition of IL-23 and no test compound)-(the amount of IL-17 produced without addition of IL-23 and no test compound))) × 100 ··· Formula 2

The inhibition ratio (%) of IL-17 production at 5 μmol / L of the test compound is shown in Table 3-1 and Table 3-2.

From this result, it was revealed that cyclic amine derivative (I) or a pharmacologically acceptable salt thereof suppresses IL-17 production.

(Example 73) Inhibitory effect of inflammatory bowel disease by TNBS-induced rat colitis model:
Cyclic amine derivative (I) or its pharmacologically acceptable substance in inflammatory bowel disease, using as a marker of colitis the large intestine injury induced by administering Trinitrobenzene slonic acid (TNBS) solution intrarectally to Wistar rats The effect of salt was evaluated. The inflammatory bowel disease model of rat by TNBS was prepared by partially modifying the method of Bobin-Dubigeon et al. (Europian Journal of Pharmacology, Volume 431, p. 103-110).

Ten week old Slc: Wistar male rats (Japan SLC Co., Ltd.) were acclimated for two weeks and subjected to an experiment at 12 weeks of age. Fasting was started in the morning on the day (Day-2) the day before TNBS rectal administration (Day 0), and grouping was performed using the weight of the day (Day-1) the day before TNBS rectal administration as an index.

The test compound (the compound of Example 29 and the compound of Example 57) was suspended at 6 mg / mL in 0.5 w / v% methylcellulose (Kanto Chemical Co., Ltd .; 0.5% MC) using a rattan mortar. It was prepared at use as a solution. The test compound was orally administered at a dose of 30 mg / kg (5 mL / kg) in the evening on Day-1 and 1 hour before the rectal administration of TNBS on Day 0. The group to which the compound of Example 29 was administered was taken as the compound administration group of Example 29 and the group to which the compound of Example 57 was administered was taken as the compound administration group of Example 57. The solvent administration group was orally administered 0.5% MC solution (solvent of each test compound) at a volume of 5 mL / kg.

TNBS was prepared on Day 0 using a feeding tube under anesthesia with pentobarbital sodium solution (Nembutal Injection, Dainippon Pharmaceutical Co., Ltd.), using a TNBS solution (Wako Pure Chemical Industries, Ltd .; 30 v / v% ethanol solution) ) Was administered rectally at a dose of 20 mg / head. After administration of the TNBS solution, the animals were allowed to stand for 1 hour, and then returned to the breeding cages to resume feeding.

The test compound was orally administered at a dose of 30 mg / kg twice a day from Day 1 to Day 4. The vehicle administration group was orally administered 0.5% MC solution at a volume of 5 mL / kg twice a day. The abdomen was opened under isoflurane anesthesia on Day 5 and the abdominal aorta was cut off and exsanguinated, then the large intestine was lifted from the anal side, the adhesion state between the large intestine and the surrounding tissue was observed, and the adhesion state is described in Table 4 Scored according to criteria.

The large intestine was removed, and the large intestine was cut at a length of 10 cm from the anal side. After longitudinal dissection of the excised colon, stool status was observed and scored according to the criteria described in Table 5.

After washing the lumen of the incised large intestine with physiological saline, an indigo carmine solution (Wako Pure Chemical Industries, Ltd.) was applied, and the ulcer condition of the large intestine was scored according to the criteria described in Table 6. The value obtained by summing the individual scores of adhesions, feces and ulcers of the large intestine was taken as the “macroscopic injury score”, and this value was used as an index for evaluation of efficacy.

The results are shown in FIG. 1 and FIG. The vertical axis in FIG. 1 and FIG. 2 indicates the macroscopic injury score (mean ± standard error, n = 21) of the large intestine, and “solvent” on the horizontal axis indicates a solvent administration group. The “compound of Example 29” in FIG. 1 indicates the compound administration group of Example 29, and the “compound of Example 57” in FIG. 2 indicates the compound administration group of Example 57. * Indicates statistical significance when compared with the vehicle administration group (Wilcoxon test) if the risk factor is less than 5%.

Rectal administration of TNBS showed a gross injury score of 6.0 ± 0.66 in the vehicle administration group. This macroscopic injury score was statistically significantly suppressed by the administration of the compound of Example 29 or the compound of Example 57 (the macroscopic injury score of the compound administration group of Example 29: 4.0 ± 0 Macroscopic injury score of the compound administration group of Example 50, 50. 50, 3.6 ± 0.63).

From these results, it was revealed that cyclic amine derivative (I) or a pharmacologically acceptable salt thereof exhibits a remarkable symptom suppressing effect on inflammatory bowel disease.

Since the cyclic amine derivative of the present invention or a pharmacologically acceptable salt thereof has excellent RORγ antagonist activity, it can be used as a therapeutic agent or prophylactic agent for inflammatory bowel disease by suppressing the function of RORγ it can.

Claims

The therapeutic agent or preventive agent of inflammatory bowel disease which contains the cyclic amine derivative shown by following General formula (I), or its pharmacologically acceptable salt as an active ingredient.

[Wherein, R 1 represents an alkyloxy group having 1 to 3 carbon atoms (wherein 1 to 3 arbitrary hydrogen atoms in the alkyloxy group may be substituted with a halogen atom), and R 2 represents R 2. Is a halogen atom, R 3 is a hydrogen atom, a halogen atom or a hydroxyl group, R 4 is a hydrogen atom or a halogen atom, and X is —C (= O) — (CH 2 ) n —R 5 or -S (= O) represents 2 -R 6, n represents an integer of 0 ~ 5, R 5 is a hydrogen atom, -OR 7, -SR 7, -S (= O) 2 -R 7 , -C (= O) -OR 7 , -N (R 7 ) R 8 , an alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms are substituted by a halogen atom) Or a heteroaryl group (in the heteroaryl group, any hydrogen atom is an alkyl group having a carbon number of 1 to 3). Is represents may.) Also have, R 6 represents an alkyl group having 1 to 5 carbon atoms, R 7 is an alkyl group (the alkyl group of which a hydrogen atom or a C 1-3, 1-3 And R 8 is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, an acyl group having 2 to 4 carbon atoms, or 1 to 3 carbon atoms). Represents an alkylsulfonyl group of ]
R 1 is an alkyloxy group having 1 to 3 carbon atoms (in the alkyloxy group, 1 to 3 arbitrary hydrogen atoms may be substituted with a fluorine atom or a chlorine atom),
R 2 is a fluorine atom or a chlorine atom,
R 3 is a hydrogen atom, a fluorine atom, a chlorine atom or a hydroxyl group,
R 4 is a hydrogen atom, a fluorine atom or a chlorine atom,
R 5 is a hydrogen atom, -OR 7 , -SR 7 , -S (= O) 2 -R 7 , -C (= O) -OR 7 , -N (R 7 ) R 8 , having 1 to 3 carbon atoms (Wherein any one to three hydrogen atoms in the alkyl group may be substituted with a fluorine or chlorine atom) or a heteroaryl group (in the heteroaryl group, any hydrogen atom is methyl) Group may be substituted)),
R 6 is an alkyl group having 1 to 3 carbon atoms,
R 7 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms may be substituted with a fluorine atom or a chlorine atom). The therapeutic agent or preventive agent of inflammatory bowel disease as described in 1).
R 1 is a methoxy group (in the methoxy group, 1 to 3 arbitrary hydrogen atoms may be substituted with a fluorine atom),
R 2 is a fluorine atom or a chlorine atom,
R 3 is a hydrogen atom, a fluorine atom or a hydroxyl group,
R 4 is a hydrogen atom or a fluorine atom,
n is an integer of 0 to 4 and
R 5 is a hydrogen atom, -OR 7 , -N (R 7 ) R 8 , an alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms are substituted with a fluorine atom) Or a 5-membered ring heteroaryl group (in the heteroaryl group, any hydrogen atom may be substituted with a methyl group),
R 6 is a methyl group or an ethyl group,
R 7 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms (in the alkyl group, 1 to 3 arbitrary hydrogen atoms may be substituted with a fluorine atom),
The agent for treating or preventing inflammatory bowel disease according to claim 1, wherein R 8 is a hydrogen atom, a methyl group, an acyl group having 2 to 4 carbon atoms or an alkylsulfonyl group having 1 to 3 carbon atoms.
R 1 is a trifluoromethoxy group,
R 2 is a chlorine atom,
R 3 is a hydrogen atom,
R 4 is a hydrogen atom,
X is -C (= O)-(CH 2 ) n -R 5 ,
n is an integer of 0 to 3,
R 5 represents a methyl group, a trifluoromethyl group, -N (R 7 ) R 8 , an imidazolyl group, a triazolyl group or a tetrazolyl group (in the imidazolyl group, the triazolyl group or the tetrazolyl group, any hydrogen atom is substituted with a methyl group) May be)),
R 7 is a hydrogen atom, a methyl group or an ethyl group,
The agent for treating or preventing inflammatory bowel disease according to claim 1, wherein R 8 is a hydrogen atom, a methyl group, an acetyl group, a propionyl group, a methylsulfonyl group or an ethylsulfonyl group.
The agent for treating or preventing inflammatory bowel disease according to any one of claims 1 to 4, which is a retinoid-related orphan receptor γ antagonist.